

Review Article

Gene \times Environment Interactions in Schizophrenia: Evidence from Genetic Mouse Models

Paula Moran,¹ Jennifer Stokes,² Julia Marr,² Gavin Bock,² Lieve Desbonnet,³ John Waddington,^{4,5} and Colm O'Tuathaigh²

¹*School of Psychology, University of Nottingham, Nottingham NG7 2RD, UK*

²*School of Medicine, University College Cork, Brookfield Health Sciences Complex, College Road, Cork, Ireland*

³*School of Life Sciences, University of Glasgow, Room 220, Bower Building, Glasgow G12 8QQ, UK*

⁴*Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland*

⁵*Jiangsu Key Laboratory of Translational Research & Therapy for Neuropsychiatric Disorders and Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China*

Correspondence should be addressed to Colm O'Tuathaigh; c.otuathaigh@ucc.ie

Received 27 March 2016; Revised 20 July 2016; Accepted 21 August 2016

Academic Editor: Joram Feldon

Copyright © 2016 Paula Moran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The study of gene \times environment, as well as epistatic interactions in schizophrenia, has provided important insight into the complex etiopathologic basis of schizophrenia. It has also increased our understanding of the role of susceptibility genes in the disorder and is an important consideration as we seek to translate genetic advances into novel antipsychotic treatment targets. This review summarises data arising from research involving the modelling of gene \times environment interactions in schizophrenia using preclinical genetic models. Evidence for synergistic effects on the expression of schizophrenia-relevant endophenotypes will be discussed. It is proposed that valid and multifactorial preclinical models are important tools for identifying critical areas, as well as underlying mechanisms, of convergence of genetic and environmental risk factors, and their interaction in schizophrenia.

1. Introduction

Schizophrenia is a psychotic illness characterised by multifaceted psychopathology and dysfunction [1–5], with a European prevalence estimate for psychotic disorders (including schizophrenia) of 1.2% [6, 7]. This debilitating disorder is characterised by heterogeneous display of positive symptoms (hallucinations, delusions, and thought disorder), negative symptoms (avolition, restricted affect, poverty of speech, and social withdrawal), and cognitive dysfunction (e.g., working memory deficits, executive function, and attentional dysfunction), which typically emerge during late adolescence and young adulthood. Antipsychotic drugs which are currently available and commonly prescribed are efficacious against positive symptoms including hallucinations and delusions but are associated with significant side effects which negatively impact on compliance [4, 8], have little beneficial effect against the negative or cognitive symptoms, and moreover are not effective in all patients [9].

Schizophrenia is also a highly heritable disorder of neurodevelopment, where the development and expression of positive or psychotic symptoms are best viewed as signifying the outcome of a pathobiological cascade which originates in early brain development [4, 10]. Research over the past decade has significantly advanced our understanding of the genetic basis of schizophrenia, identifying risk loci, and suggesting biologically plausible mechanisms by which genetic risk is conferred [11], but much is still unknown [9]. A multitude of factors including, but not restricted to, gene \times environment ($G \times E$) and gene \times gene ($G \times G$) interactions, epigenetic modifications, and considerable heterogeneity at a genetic and phenotypic level, complicate our understanding of the role of these genes in the disorder and the translation of genetic advances into novel biological treatment targets [12, 13]. $G \times E$ interactions in schizophrenia might reflect genetic control of responses to protective or adverse environmental factors, as well as context-dependent phenotypic expression.

However, recent articles have highlighted the challenges associated with selecting appropriate statistical methods for identifying $G \times E$ interactions in schizophrenia and other neuropsychiatric disorders [14, 15]

Adoption and twin studies have confirmed that schizophrenia has a significant heritability component [16] with risk to develop schizophrenia or a related psychotic disorder positively correlated with degree of genetic similarity [17]. However, twin studies conducted in schizophrenic patients indicate that genes contribute no more than 50% to aetiology suggesting that developmental and environmental factors also have a major role to play [9]. Epidemiological studies have suggested that a diversity of factors including prenatal infection/immune activation, paternal age, malnutrition, hypoxia-related obstetric complications, and childhood/adolescence social stress and cannabis abuse are associated with increased risk for development of this disorder [2]. A “multihit” model has been proposed, and two crucial time windows associated with early brain development and maturation during adolescence have been identified as particularly sensitive periods for exposure to adverse environmental events, which could eventually trigger schizophrenia-relevant biological sequelae [18].

Recent genomewide association study (GWAS) analyses have identified multiple common schizophrenia risk alleles, each contributing a small effect, although they have provided mixed support for some of the more prominent common risk alleles identified in case-control and family-based genetic association studies [5, 19, 20]. Additionally, the discovery of microRNA changes and copy number variations (CNVs) in schizophrenia highlight the contribution and impact of rare and highly penetrant alleles in conferring genetic risk for schizophrenia [21, 22]. If a multiple-hit hypothesis is in fact an underlying model for the majority of cases for schizophrenia, it is likely to involve a combination of single nucleotide polymorphisms (SNPs), rare penetrant mutations, and environmental factors [23]. A large number of $G \times E$ interaction studies in patients with schizophrenia have focused on one candidate gene interacting with a specific environmental exposure. Since these studies have a specific prior hypothesis, they can be investigated with a modest sample size. Recent reviews of $G \times E$ interactions across clinical and preclinical studies in schizophrenia have however highlighted the relative paucity of relevant clinical data, noting that several of the animal models discussed in the present review have consequently selected $G \times E$ manipulations based on either combinations of genetic and environmental factors which have been (a) independently associated with schizophrenia, but not in combination, and/or (b) target common biological pathways implicated in schizophrenia, for example, disturbance of dopaminergic (DA) transmission [24–26].

$G \times E$ interactions in schizophrenia may also take the form of environmental factors impacting on DNA methylation, producing changes in gene expression through epimutations [27, 28]. Epigenetic factors represent an important mechanism whereby the adverse effects of environmental risk factors may impact gene expression. This topic has previously been discussed in more detail in relation to schizophrenia (e.g., [27]) and genetic models of schizophrenia [28]. One

notable example is advanced paternal age (APA), which has been shown to be a risk factor for schizophrenia [29] as well as a host of other adverse neurodevelopmental outcomes (attention deficit hyperactivity disorder (ADHD), 30; autistic spectrum disorder (ASD), [30]). The predominant hypothesis in the field postulates age-related accumulation of *de novo* mutations in paternal sperm DNA [31], with a growing body of evidence suggesting that epigenetic changes in these cells could also be implicated [32, 33].

The present review will seek to summarise recent research which has been conducted on modelling of $G \times E$ interactions in schizophrenia using preclinical genetic models, primarily constitutive knockout or transgenic lines. There will be an emphasis placed on summarising evidence for psychosis-relevant features in the models, together with any evidence for mechanistic-based interrogation of the underlying pathophysiology.

2. Genetic Basis of Schizophrenia

Meta-analyses of twin and adoption studies have shown that heritability accounts for approximately 70% of disease risk in schizophrenia [34], where the magnitude of risk varies widely, from relatively modest odds for common genetic variants to substantial risks due to rare variants. Rare chromosomal deletions and duplications can increase risk for the disorder, with the magnitude of the increase in risk substantially greater than that observed for common variants [35–37].

GWAS data has implicated several candidate genes with a strong link to the pathophysiology of the disorder, while questioning the impact of hitherto prominent susceptibility targets (e.g., *disrupted-in-schizophrenia-1* (*DISC1*), *neuregulin-1* (*NRG1*)) [38]. The most recent analysis has identified 108 agreed loci that contribute to risk for schizophrenia; specifically, the Psychiatric Genomics Consortium (PGC) collaborative molecular genetic study of almost 37,000 patients with schizophrenia and 113,000 healthy controls identified 83 novel risk markers and replicated 25 existing markers [39]. The study pointed particularly to genes involved in neurodevelopment, the immune and stress response, glutamatergic neurotransmission, and DA D2 receptor activity.

CNV analyses which detect structural variants in the form of submicroscopic deletions and duplications of DNA have identified rare *de novo* and inherited variants that confer high risk for schizophrenia (Odds Ratio = 3–20) [40]. An exome-sequencing study involving 2536 schizophrenia cases and 2543 controls demonstrated a polygenic burden primarily arising from rare (less than 1 in 10,000), disruptive mutations distributed across many genes [41]. These authors were able to detect several small and highly enriched sets, notably of genes related to N-methyl-D-aspartate (NMDA) receptor-associated postsynaptic density-95 (PSD-95) protein complexes, activity-regulated cytoskeleton- (ARC-) associated interacting proteins and fragile \times mental retardation protein (FMRP) targets [42].

Importantly, some of the genetic factors linked with increased risk for schizophrenia also display association to broader phenotypes including bipolar disorder, as well as major depression, ADHD, and autism [43], suggesting that

clinical overlap between these disorders may in part reflect a shared genetic basis. In a recent combined GWAS of 19779 bipolar disorder and schizophrenia cases versus 19423 controls, in addition to a direct comparison GWAS of 7129 schizophrenia cases versus 9252 bipolar disorder cases, the authors identify five previously identified regions reaching genome-wide significance as well as a novel locus [44]. These authors reported a significant correlation between a bipolar disorder polygenic risk score and the clinical dimension of mania in patients with schizophrenia. Overlapping disease pathways may, in part, explain shared symptoms across diagnoses, as well as multiple diagnoses within patients [45].

3. Mutant Models of $G \times E$ Interactions in Schizophrenia

Interactions between genetic risk and environmental stressors at various stages of life appear important in the development of schizophrenia [46–48]. Preclinical genetic models provide tools for assessing the relative contribution of genes, exposure to environmental pathogens, and their interaction, on the development of schizophrenia-relevant phenotypes [25, 48, 49]. Preclinical modelling of $G \times E$ interactions related to schizophrenia has typically involved examining the phenotypic consequences of epidemiologically relevant but also translationally valid, experimental manipulations in various candidate risk gene mutant models [50, 51]. Combining an environmental challenge with a genetic mutation can produce both protective and adverse effects. It has been noted that the potential to generate such results should be incorporated within the study design and that exclusively focusing on a limited set of prespecified outcome measures may exclude the possibility of reporting such unexpected and complex bidirectional results [28]. Particularly in the context of evidence for a shared genetic basis underlying several major neuropsychiatric disorders, the discovery of novel behavioural phenotypes in preclinical models of $G \times E$ interactions has the potential to inform us about the role of the environment in evoking diverse clinical outcomes in patients with the same mutation.

Timing of the environmental insult is an important factor that needs to be considered during the development and evaluation of the $G \times E$ model. Mutant modelling of $G \times E$ interactions in schizophrenia studies has typically involved environmental manipulations at particular periods of brain development (e.g., early pregnancy or adolescence) which are regarded as important to the pathogenesis of schizophrenia. These critical periods of brain development correspond to early life (pre-, peri-, and early postnatal period) or later (adolescent) stages in humans [52, 53].

While many of the studies discussed below, which aim to simulate $G \times E$ interactions implicated in psychosis in rodent models, consist mostly of descriptive analyses, a growing number of studies are starting to provide important mechanistic insight into the molecular/cellular basis underlying such interactions. Elucidating the biological mechanisms underlying synergistic $G \times E$ effects on emergence of neuropsychiatric phenotypes necessitates interrogation of the molecular basis of the observed phenotypes.

4. Modelling Schizophrenia in Rodents

While it is impossible to model schizophrenia *per se* in mice or other rodents, three important criteria need to be satisfied in order for any experimental model to claim validity for the disorder. Firstly, the model should reflect, at least in part, the etiopathological basis of the disorder. Secondly, while research has emphasized the neurodevelopmental aspect of schizophrenia, its clinical onset is postpubertal. This fact emphasises the importance of examining the data of young animals as part of any $G \times E$ interaction modelling effort, so that the trajectory from insult during early development or young adulthood to the emergence of adult phenotypes can be established. Thirdly, the experimental model should reflect endophenotypes relevant to schizophrenia in adulthood. Endophenotypes are quantifiable, intermediate disease features that bridge the gap between the overt manifestations of schizophrenia and underlying risk genes [54]. Earlier reviews have highlighted the value of utilising endophenotypic endpoints in preclinical genetic studies, where intermediate biological or behavioural phenotypes are less susceptible to confounding influences and are therefore easier to investigate [26]. Schizophrenia-relevant endophenotypes include behavioural deficits (e.g., working memory impairment, deficits in sensory or sensorimotor gating, and social withdrawal) and several histological/structural changes such as enlarged lateral ventricles and deficits in a specific subtype of interneurons in the cortex.

Recently, efforts have been made to identify equivalent behavioural domains and functional assays between humans and animals, including the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS). More recently, the Research Domain Criteria (RDoC) initiative from the National Institute of Mental Health (NIMH) aims to reclassify psychiatric disorders according to basic dimensions of functioning, where each behavioural domain is studied across multiple levels of analysis, from genes to neural circuits to behaviour in both animal models and humans, assuming that these behavioural domains share more or less similar underlying mechanism across species [55]. RDoC includes the following domains: negative valence systems (fear, anxiety, and loss), positive valence system (reward learning, reward evaluation), cognitive systems (attention, perception, working memory, and cognitive control), systems for social processes (attachment formation, social communication, perception of self, and perception of others), and arousal/modulatory systems (arousal, circadian rhythms, sleep, and wakefulness).

5. Modelling Environmental Risk Factors Relevant to Schizophrenia in Rodents

There is a general consensus among schizophrenia researchers that diverse biological, environmental, and psychosocial insults, across the lifespan, accumulate in their adverse impact on an already developmentally compromised brain to result in the development of psychotic illness [26, 48].

Consistent with the well-considered “stress-vulnerability” aetiological model, these extend from early biological and psychosocial insults during the prenatal or perinatal period (including winter birth, maternal infections or immune challenge, and other obstetric complications [2, 48]), through exposure to adversity during infancy and childhood (e.g. societal factors, childhood abuse; [56]), to pathogenic factors present during adolescence and young adulthood (exposure to psychosocial stressors, prolonged exposure to drugs of abuse including cannabis [57]). As noted above in relation to genetic factors, numerous environmental factors associated with schizophrenia and other psychotic disorders are also associated with a range of other neurodevelopmental and neuropsychiatric outcomes, including autistic spectrum disorder, attention-deficit hyperactivity disorder, and epilepsy [20], leading some authors to propose that schizophrenia is best conceptualised as one of a spectrum of clinical outcomes that result from exposure to selected genetic or environmental factors, or both [20]. Translational efforts to model such factors on rodents have generally sought to develop ethologically appropriate (e.g., maternal deprivation, postweaning social isolation, or social defeat during adolescence to study the effects of psychosocial stress on neurobehavioural measures across development in mice/rats) or practicable and exposure-relevant biological manipulations (e.g., inflammatory responses after infection and cytokine-mediated effects on brain development using polyinosinic-polycytidylic acid (Poly I:C) and lipopolysaccharide (LPS) in rats/mice) to investigate the biological underpinnings of G × E interactions.

6. Infection and Schizophrenia

It is well established that prenatal influenza exposure is associated with increased risk of developing schizophrenia in the offspring [58, 59]. This risk liability has been shown to extend to other viral and bacterial agents, as well as exposure to parasitic agents such as *Toxoplasma gondii* [2, 60]. The emergence of schizophrenic symptomatology in adult offspring has been shown to be dependent upon maternal infection at different gestational points throughout pregnancy [61, 62], which is an important consideration when developing valid animal models of maternal infection in schizophrenia. While a multitude of infectious agents have been associated with increased risk for schizophrenia, it is proposed that the common pathophysiological mechanism underlying their “schizophrenogenicity” involves activation of the maternal immune system [2, 62].

Preclinical experimental models have been developed which involve prenatal exposure to infection, immune activation, or another relevant biological insult. These models have included gestational exposure to human influenza virus, the bacterial endotoxin LPS, and Poly I:C, a synthetic analogue of double-stranded RNA which is recognized as an infectious pathogen by the human immune system [63]. In the rodent prenatal Poly I:C model, administration of Poly I:C to pregnant dams causes elevations in maternal serum cytokines that are accompanied by emergence in adulthood of behavioural and neural phenotypes related to those evident

in schizophrenia [64]. Timing of immune challenge is a significant determinant of brain and behaviour outcomes in subsequent offspring. It has been shown that the effects of maternal immune challenge during gestation between early (gestational day [GD] [9]) and late (GD17) pregnancy periods in mice are dissociable in terms of foetal brain cytokine responses to maternal inflammation and subsequent functional effects [65, 66]. These challenge periods correspond to the end of the first trimester (GD9) and middle/late phase of the second trimester (GD17) in humans [67, 68].

Poly I:C treatment during early pregnancy is associated with schizophrenia-related endophenotypes in adult offspring including deficits in prepulse inhibition (PPI [67, 68]) as well as latent inhibition (LI [69]), two measures of preattentive and selective attention processes, respectively, which are disturbed in schizophrenia. Across various measures of social interaction, both early and late gestational treatment Poly I:C in dams has been shown to disrupt sociability and social cognition [66, 70, 71]. Similarly, offspring of Poly I:C-treated dams display a hyperexploratory phenotype in a novel environment [64], as well as increased behavioural sensitivity to DA agonists and NMDA receptor antagonists [72, 73]; both of these features are considered proxy measures for the positive symptoms of schizophrenia. Structural brain endophenotypes associated with schizophrenia have also been demonstrated in the brains of adult offspring of Poly I:C treated mice; these include lateral ventricular enlargement and decreased hippocampal volume [74, 75].

As the majority of individuals exposed to neurodevelopmental insults such as infections do not develop schizophrenia in adulthood, it is important to assess the additive and interactive effects of infection and genetic vulnerability on the development of schizophrenia-relevant endophenotypes.

6.1. *NRG1* × Immune Challenge. *Neuregulin-1 (NRG1)* is putative risk gene which has been widely studied in relation to its association with schizophrenia [76–78]. In meta-analysis, the association between the *NRG1* schizophrenia-associated risk haplotype (HapICE, first reported by Stefansson et al. [76]) and schizophrenia has proved replicable [77]. *NRG1* belongs to a family of growth factors which are encoded by four genes (*NRG1-4*); it has greater than 30 isoforms, grouped into six “types” (I–VI) that are differentiated on the basis of N-terminal sequence, expression of the α or β epidermal growth factor- (EGF-) like domain, and presence of a transmembrane (TM) region [79, 80]. *NRG1* proteins are ligands for ErbB receptor tyrosine kinases; this, in turn, activates intracellular signalling pathways that are known to play a prominent role in diverse developmental processes implicated in schizophrenia [79, 80]. *NRG1* is expressed in diverse brain areas, including the PFC, hippocampus, cerebellum, and substantia nigra in both humans and rodents [80]. *NRG1* isoforms differ in domain structure and expression levels in various tissues/cells during brain development and, later, in adulthood; isoform-specific roles and properties, particularly in relation to the *NRG1*-schizophrenia association, remain poorly understood [80]. This level of genetic complexity highlights the difficulty associated with generating accurate preclinical

genetic models of *NRG1* dysfunction in schizophrenia. Clinical genetic analyses have supported the association between *NRG1* variation, inflammatory function, and neurogenesis. Interaction between the genes encoding the proinflammatory cytokine interleukin 1 β (IL-1 β) and *NRG1* genotype increases the risk of schizophrenia and shortens the age of onset for the disorder [81]. Additionally, a missense mutation in *NRG1* has been reported to increase activation of proinflammatory cytokines such as interleukin 6 (IL-6), tumor necrosis factor α (TNF- α), and interleukin 8 (IL-8) in patients with schizophrenia [82].

Various *NRG1* knockout and transgenic mouse lines have been developed to study the relationship between altered *NRG1* signalling and impact on behavioural and brain endophenotypes relevant to schizophrenia [26, 83]. Mice with heterozygous knockout of the transmembrane- (TM-) domain truncation of exon 11 *NRG1*, which is associated with the disruption of several *NRG1* splice variants, display increased novelty-induced hyperactivity, which is reversed by antipsychotic treatment [76, 84, 85]. Disruption to PPI has also been reported in the TM-domain *NRG1* mutant line [86–88], and they also display deficits in social interaction [85].

Comparisons with alternative TM-domain or more isoform-specific *NRG1* deletions indicates that differences in the targeting strategy, as it relates to the *NRG1* gene, can produce very different effects across various neurobehavioural measures. For example, in contrast with the exon 11 TM-domain lines, mutant mice with targeted disruption of type I/type II *NRG1* do not show a hyperactive phenotype [89, 90]. Similarly, no significant behavioural impairments, aside from mild cognitive deficits, were observed in a TM-domain mutant line with a truncation from exon 9 [91].

O'Leary et al. [92] examined the unique and combined effects of prenatal immune challenge (*via* administration of Poly I:C at GD9) and postnatal cross-fostering (a control procedure which can also act as a stressor, where offspring are separated from dams and raised by surrogate mothers) in mice with partial TM-domain (exon 9) deletion of *NRG1*. In this study, distinct phenotypic effects across schizophrenia-related behavioural measures (social interaction, PPI, and open-field exploration) were observed for both individual environmental variables as well as interactions between these factors and genotype [92]. *NRG1* mutants demonstrated impaired social novelty preference, PPI, and a sex-specific (females only) decrease in spatial working memory performance, irrespective of exposure to the stressor. Poly I:C treatment also disrupted PPI and working memory performance across both genotypes. Combining *NRG1* disruption and prenatal immune challenge caused deficits in social behaviour and spatial working memory, whereas combining *NRG1* disruption with the early life stressor (cross-fostering) impaired social novelty preference, a measure of social cognition. No synergistic effect of *NRG1* disruption and prenatal immune challenge was observed in relation to PPI, which may be attributable to a masking effect of *NRG1*-related PPI disruption on potential *NRG1* \times prenatal immune challenge interactions on sensorimotor gating. However, the combination of prenatal immune challenge and cross-fostering (i.e., E \times E) also produced several behavioural deficits in the

open field, social behaviour, and PPI. The results of this study suggest that the emergence of schizophrenia-relevant endophenotypes can arise from multiple, often very complicated, interactions involving individual genes interacting with several biological and psychosocial factors.

6.2. *DISC1* \times Immune Challenge. *DISC1* is a prominent schizophrenia risk gene, which was originally identified at the breakpoint of a balanced chromosomal translocation cosegregating with mental disorders in a large Scottish kindred [93]. Subsequent clinical genetic studies have identified evidence for involvement of common and rare risk variants at this locus in the etiology of a range of neuropsychiatric disorders, including schizophrenia, schizoaffective disorder, bipolar disorder, and recurrent depressive disorder [94, 95]. *DISC1* is an essential synaptic protein, which interacts with a wider molecular network to mediate processes associated with cellular and synaptic function [96]. Mutant models of *DISC1* gene function display anatomical, behavioural, and pharmacological phenotypes relevant to several neuropsychiatric disorders, including schizophrenia and depression [97–103]. As with the *NRG1* mutant data, these *DISC1* mutant phenotypic analyses again illustrate how different mutations in the same gene can result in divergent phenotypic outcomes. For example, a transgenic line with inducible and reversible expression of a *DISC1* C-terminal fragment under the calcium/calmodulin-dependent protein kinase II alpha (α CaMKII) promoter demonstrated impaired social functioning and disruption of spatial working memory [99]. In a transgenic line with expression of a dominant-negative truncated form of *DISC1* under the α CaMKII promoter, mutants exhibited novelty-induced hyperactivity but no other major phenotypes [98]. Double transgenic mice expressing human *DISC1* under the cytomegalovirus (CMV) promoter with tetracycline under the α CaMKII promoter showed a hyperactive phenotype, as well as deficits in social interaction and spatial memory [101]. Another group described two mouse line carrying point mutations in *DISC1* (L100P and Q31L), where abnormalities associated with schizophrenia were observed in the L100P line; these included deficits in PPI and LI, as well as working memory, many of which were shown to be reversible by antipsychotic administration [97].

Employing the Poly I:C immune challenge procedure, Lipina et al. [104] demonstrated that the mutant offspring of L100P dams who had been given a single injection of Poly I:C on GD9 demonstrated more prominent PPI and LI deficits, as well as impaired working memory and sociability, relative to L100P controls or both challenged and unchallenged wildtype controls, where moderate deficits in these tasks were already observed following the genetic or environmental manipulation alone. Coadministration of an IL-6 antagonist blocked the disruptive effects of prenatal Poly I:C on PPI and LI performance in L100P mice, providing a direct link between Poly I:C treatment and behavioural disruption in these mice.

The phenotypic effects of combining prenatal immune challenge with *DISC1* disruption were also described in a study conducted in mice with inducible expression of mutant *hDISC1* in forebrain neurons [50, 101]. Poly I:C treatment increased anxiety in mutants and controls in the open field,

and both challenged and nonchallenged *DISC1* mutants displayed lateral ventricular enlargement relative to controls. Male *DISC1* mutant offspring of dams treated with Poly I:C at GD9 demonstrated decreased social approach behaviours, as well as an anxiogenic phenotype (less time in the open arms of the elevated plus maze) and depression-like behaviours (i.e., decreased latency to immobility in the forced swim test). These behavioural deficits were accompanied by altered serotonergic neurotransmission in the hippocampus, decreased hypothalamic-pituitary-adrenal (HPA) axis reactivity and attenuation of genotypic enlargement of the lateral ventricles, as well as differential modulation of secretion of inflammatory cytokines [50].

Another study examined the interaction of *DISC1* mutation with *neonatal* treatment with Poly I:C between postnatal days 2 and 6 [105]. While neither the *DISC1* mutation nor neonatal immune challenge were independently associated with any phenotypic effects, transgenic mice expressing a dominant-negative form of *DISC1* displayed a pronounced schizophrenia-related phenotype across several cognitive endophenotypes (spontaneous Y-maze alternation [which measures working memory processes], recognition memory, and contextual fear memory) following neonatal immune challenge. Social interaction and MK-801-induced hyperactivity were also selectively altered in Poly I:C-treated *DISC1* mutants. These behavioural deficits were accompanied by a decrease in parvalbumin-positive interneurons in the medial prefrontal cortex (a cellular endophenotype for schizophrenia) of *DISC1* × neonatal immune challenge mutants. It was later shown, employing the same experimental design, that the antipsychotic drug clozapine successfully reversed the recognition memory deficits in *DISC1* mutants exposed to neonatal Poly I:C [106].

A recent study examined the interaction between *DISC1* genotype, employing the transgenic model of inducible expression of dominant-negative mutant human *DISC1*, and prenatal exposure to the toxin lead (Pb²⁺), to assess the development of neuropsychiatric phenotypes in resultant lead-exposed offspring [107]. Lead exposure was associated with the expression of increased anxiety, disruption of PPI, increased responsivity to the NMDA receptor antagonist MK-801, and ventricular enlargement (also observed in nonstressed *DISC1* mutants versus controls). The authors reported several, often sex-specific, synergistic effects, demonstrating more pronounced PPI deficits, heightened MK-801 responsivity, and alterations in exploratory activity and ventricular volume in *DISC1* mice exposed to lead.

6.3. *Nurr1* × Immune Challenge. *Nurr1* is a member of the orphan steroid hormone receptor family which is involved in key processes including differentiation, migration, and survival of midbrain DA neurons [108], as well as regulation of the expression of genes which are crucial for DA neurotransmission [109]. The combination of partial knockout of *Nurr1* and prenatal immune activation *via* late gestational Poly I:C administration resulted in additive effects on locomotor hyperactivity in a novel environment and PPI disruption, where deficits across both measures were already observed following genetic disruption of *Nurr1* or exposure to Poly I:C

alone. In contrast, multiplicative disruptive effects of both genetic and environmental manipulations were observed for measures of attentional function including LI persistence and a measure of sustained attention [110]. Synergistic interactions between *Nurr1* haploinsufficiency and prenatal immune activation on DA D2 receptor density in the nucleus accumbens core and shell were also reported, as well as a significant decrease and increase in tyrosine hydroxylase and catechol-O-methyltransferase (COMT) density, respectively, in the medial prefrontal cortex [110].

7. Cannabis Use and Schizophrenia

Recent epidemiological surveys have calculated mean estimates of lifetime prevalence of cannabis use of 25% and 35.8% among youth aged 15-16 in the UK and USA, respectively [111, 112]. Therefore, a significant number of young people are exposed to cannabis during an important neurodevelopmental stage characterised by maturation of neural circuitry across several brain areas implicated in schizophrenia and other neuropsychiatric disorders. Lifetime cannabis use increases risk for developing a psychotic disorder [113, 114], where the risk quotient is highest among individuals who use cannabis during adolescence [115–118]. However, despite high prevalence estimates for lifetime cannabis use, a relatively small proportion of cannabis users go on to develop sub-clinical symptoms or a clinical psychotic disorder [119]. This may be explained by the interaction between cannabis-related psychosis risk and genetic disposition, as well as the copresence of other adverse environmental conditions [120]. It may also reflect differential concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol in cannabis products. THC is the principal psychotomimetic ingredient of cannabis; cannabidiol, in contrast, is a cannabinoid which can exert anxiolytic and potentially antipsychotic effects [117, 119].

A recent analysis, conducted in a population-based sample, revealed a negative association between cannabis use in early adolescence and cortical thickness (a morphological endophenotype for schizophrenia) in male adolescents with a high genetic risk for schizophrenia, as indicated by their risk profiles across 108 genetic loci identified by the Psychiatric Genomics Consortium in a large genome-wide comparison of patients with schizophrenia and control individuals [121]. G × E studies examining the link between cannabis and psychosis in humans face the challenge of conclusively excluding the possibility that individuals with a particular genotype or profile of exposure to environmental adversity may be more likely to use cannabis, as opposed to cannabis exposure independently affecting the pathway to psychosis [122]. Delta-9-tetrahydrocannabinol (THC) is the principal psychotomimetic ingredient of cannabis; cannabidiol, in contrast, is another component of cannabis which is thought to exert anxiolytic effects [123]. Prolonged exposure to THC during the period corresponding to adolescence in rats and mice is associated with the emergence of deficits across several schizophrenia-related endophenotypes, including attentional and memory function (PPI, recognition memory), novelty-induced hyperactivity [123], and deterioration in

reinforcement learning performance [124]. It is also accompanied by neuronal hyperactivity in the mesocorticolimbic DA pathway as well as modification of prefrontal cortical molecular pathways [125]. Cannabinoid modulation of activity of DA projections from the brain stem to the striatum, in particular, has been linked with the development of cannabis-induced psychosis [126].

7.1. *NRG1* × Cannabis Exposure during Adolescence. A putative association between *NRG1* genotype and cannabis-related psychosis has not yet been examined in clinical samples. A genome-wide linkage scan, and follow-up association analysis, for cannabis dependence in African-American and European-American families, revealed that *NRG1* variation was associated with increased risk for cannabis dependence in African-Americans, and this effect was pronounced in females [127].

Male TM-domain *NRG1* mutant mice have shown increased susceptibility to several of the neurobehavioural effects of acute THC relative to wildtype controls. These genotypic effects have included greater sensitivity to the PPI-enhancing and anxiogenic effects of THC, as well as its locomotor activity suppressing effects [128–130]. These authors also observed that THC-induced increase in immediate early gene (*c-fos*) expression was greater in the shell of the nucleus accumbens, central nucleus of the amygdala, paraventricular nucleus, and dorsolateral bed nucleus of the stria terminalis of *TM-NRG1* mutants relative to controls [129]. Adding complexity to the interpretation of G × E effects in this model and suggesting the presence of second-level E × E interactions, this genotype-dependent increase in *c-fos* expression was only observed in mice who had been subjected to behavioural assessments. In a complementary manner, *TM-NRG1* mutants also demonstrated increased tolerance to the locomotor suppressant and anxiogenic effects of the synthetic cannabinoid CP 55,940, administered during adulthood [131]. *TM-NRG1* mutants were also resistant to the cannabinoid-induced decrease in investigative social behaviours compared to controls [132]. The latter study also showed that several of adolescent THC effects on cannabinoid receptor 1 (CB1R) and 5-HT_{2A} receptor binding (decreased in *TM-NRG1* mutants, increased in wildtypes) in the substantia nigra and insular cortex were genotype-dependent. Adolescent THC also selectively increased NMDA receptor binding in the auditory cortex, cingulate cortex, and hippocampus of *TM-NRG1* mutants [132], as well as inducing differential expression of proteins implicated in NMDA receptor trafficking and glutamatergic function in the hippocampus of adolescent THC-treated *TM-NRG1* mutants versus controls [133].

Cannabidiol is another psychoactive component of cannabis which has been reported to possess anxiolytic [134] and putative antipsychotic properties [135]. Long and colleagues examined the neurobehavioural effects of chronic cannabidiol during adulthood in *TM-NRG1* mutants relative to controls [136]. Chronic cannabidiol selectively enhanced social interaction and increased GABA_A receptor binding in the granular retrosplenial cortex in *TM-NRG1* mutants but had no effect on PPI or novelty-induced exploratory activity [136]. Collectively, studies conducted on THC, synthetic

cannabinoid, and cannabidiol effects in TM-domain *NRG1* mutants would indicate altered sensitivity to the neurobehavioural effects of this class of drugs, in a manner which is dependent upon timing and duration of treatment.

7.2. *DISC1* × Cannabis Exposure during Adolescence. A recent study investigated the interaction, at a preclinical level, between mutation in *DISC1* and the effects of chronic adolescent administration of THC [137]. In this model, a putative dominant-negative form of *DISC1* (*DN-DISC1*) which is expressed under the control of the alpha-CAMKII promoter in forebrain pyramidal neurons, chronic treatment with THC during adolescence (postnatal days 28–48) worsened deficits in cue-dependent fear memory in *DN-DISC1* mice, while neuronal activation induced by fear memory retrieval was also selectively impaired in *DN-DISC1* mice. *DN-DISC1* mice also demonstrated deficits in contextual fear memory irrespective of treatment condition. The combinatorial effect of adolescent THC exposure and *DN-DISC1* expression on the endocannabinoid system was also indicated by a synergistic reduction in synaptic CB1R expression in the prefrontal cortex, hippocampus, and amygdala.

7.3. *COMT* × Cannabis Exposure during Adolescence. *COMT* is an enzyme involved in the catabolism of catecholamines and is the principal enzyme controlling the metabolism of DA in the prefrontal cortex [138]. A common functional polymorphism in the *COMT* gene, the Val158Met variant, has been associated with differential reactivity to stressful stimuli. Individuals with the *COMT* Val/Val (high enzyme activity) genotype exhibit decreased affective reactivity to stress relative to carriers of Met/Met, the low enzyme activity allele [139]. Studies have shown that the disruptive effects of childhood abuse on adult emergence of cognitive deficits [140] and frequency of self-reported psychotic experiences [141] are present only in *COMT* Met/Met carriers. In one of the first clinical G × E reports reported for schizophrenia, risk to develop psychosis was shown to be highest among those who used cannabis during adolescence and were *COMT* Val/Val carriers [142]. Preclinical genetic studies employing a constitutive *COMT* gene knockout model, which looked at the interaction between chronic intermittent THC and Win 55,212 (a synthetic CB1R agonist) exposure during adolescence and *COMT* deletion, demonstrated that *COMT* genotype modulated responsivity to adolescent cannabinoid effects in relation to hyperactivity in a novel environment, working memory, and PPI [123, 143]. Specifically, THC treatment reversed enhancement of working memory in *COMT* knockout mice and produced changes in exploratory activity and PPI that were not observed following *COMT* knockout or THC treatment alone. These deficits were accompanied in a genotype-dependent manner by changes across morphological measures of DA-ergic and GABA-ergic function [144].

8. Social Stress and Schizophrenia

Exposure to psychosocial stressors, particularly at developmentally important time points, has been shown to both play a role in the development of a psychotic disorder and

precipitate the onset of psychotic illness when the stressful experience occurs closer to the onset of the disorder [144–147]. One particular social stressor which has been both linked with increased risk for schizophrenia and modelled in preclinical assays is social defeat, which refers to the defeated feeling of subordination which is experienced following an adverse social encounter [148, 149]. Animals studies have consistently shown that exposure to social defeat is associated with changes across several schizophrenia-related endophenotypes, as well as HPA axis function, and corticolimbic DA neurotransmission (see [150] for detailed review of evidence). Generally, rats or mice subjected to social defeat demonstrate impaired social behaviour, as well as increased behavioural signs of anxiety and depression [151, 152].

8.1. *NRG1* × Social Stress. The combined effect of *NRG1* heterozygous knockout and chronic social defeat stress (via intermittent access to an aggressive CD1 strain conspecific) during adolescence produced genotype-dependent working memory deficits and elevated basal cytokine levels during adulthood in *TM-NRG1* mutant mice relative to controls [86]. *TM-NRG1* mutants displayed a genotypic increase in novelty-induced activity, disruption of PPI and social novelty preference, and decreased anxiety relative to wildtypes. However, the combination of repeated social defeat stress and partial *NRG1* knockout produced deficits in the Y-maze spontaneous alternation task (a measure of working memory), which were not observed in stressed wildtype controls. In contrast, in the sucrose preference test (a measure which is utilised to model anhedonia in rodents), stressed control mice displayed reduced sucrose preference (i.e., an “anhedonic” profile), whereas no such effect was observed in stressed *NRG1* mutants. Another recent study which compared the effects of acute and chronic exposure to a nonsocial stressor, restraint stress, during adolescence in *TM-NRG1* mutants versus controls reported increased sensitivity to the anxiogenic effects of acute stress exposure in mutants [153]. Chronic intermittent stress during adolescence also produced deficits in PPI in *NRG1* mutants relative to both stressed wildtypes and nonstressed mice belonging to both genotypes. *NRG1* mutants also demonstrated decreased corticosterone levels, as well as increased apical dendritic spine density and decreased apical dendritic lengths and complexity in layer II/III pyramidal neurons of the medial prefrontal cortex, following chronic restraint stress.

8.2. *DISC1* × Social Stress. The phenotypic effects of social defeat stress during adulthood in mice were examined in *DISC1* L100P and Q31L (a *DISC1* line which demonstrates more affective disorder-related phenotypes and fewer psychosis-relevant phenotypes than the L100P line) mutants [154]. They reported decreased vertical activity levels during exploration in a novel environment, as well as social interaction in mice with heterozygous mutation in *DISC1* (L100P) following exposure to social defeat. While L100P mice displayed a deficit in PPI, and both L100P and Q31L mice displayed disruptions in LI, social defeat did not worsen deficits in these tasks for any group. Social defeat stress during

adulthood was also associated with increased immobility in the forced swim test, as well as an anhedonic profile in the sucrose consumption test, but these effects were not genotype-dependent.

Another study employed the C'-truncated *DN-DISC1* model, where expression is under the control of the widely expressed prion protein promoter. Mutants and controls were subjected to three weeks of social isolation during middle and late adolescence (postnatal days 35–56). This manipulation resulted in the emergence of schizophrenia-related behavioural deficits, including PPI disruption, increased immobility in a forced swim test (a measure of behavioural despair which has been used to model apathy), and increased methamphetamine-induced locomotion, in mutants relative to isolated wildtypes and nonisolated mice of both genotypes [155]. *DN-DISC1* × isolation mice also displayed decreased tyrosine hydroxylase expression, total tissue DA levels, and basal extracellular DA in the frontal cortex relative to all other genotype and environmental conditions. The same genotype-dependent effect of increased DA release was observed in the nucleus accumbens of isolated *DN-DISC1* mutants relative to all other groups. The observed behavioural and cellular endophenotypes were rescued by administration of the glucocorticoid receptor antagonist RU-486, suggesting that the heightened stress-induced corticosterone response in *DN-DISC1* × isolation mice might represent the mechanism underlying the schizophrenia-relevant behavioural and cellular phenotypes. A recent follow-up study which assessed DNA methylation of HPA-axis/glucocorticoid-related genes in the mesocortical DA-ergic neurons of *DN-DISC1* × isolation mice revealed altered DNA methylation of *tyrosine hydroxylase*, *brain-derived neurotrophic factor (BDNF)* and *FK506 binding protein 5* genes [53]; these epigenetic changes were once again reversed by glucocorticoid receptor antagonist treatment.

9. Other Genes Implicated in Pathogenesis of Schizophrenia: Evidence for G × E Interactions

9.1. *Dystrobrevin Binding Protein 1 (DTNBPI)*. Several studies have identified *DTNBPI* (or *dysbindin-1*) as a potential risk gene for schizophrenia [156–158]. Genetic association studies have shown that variations in this gene are associated with abnormal prefrontal cortical function in patients with schizophrenia, as well as episodic and working memory performance in healthy subjects [159–161]. The relevance of regionally specific loss of *DTNBPI* expression to the pathophysiology of this neurodevelopmental disorder is highlighted by postmortem studies revealing a decrease in *DTNBPI* expression in neurons of the dorsolateral prefrontal cortex and hippocampus [162, 163]. At a cellular level, *DTNBPI* is mainly expressed in synaptic sites and plays an important role in synaptic homeostasis by regulating neurotransmitter vesicle exocytosis and vesicle biogenesis in neurons. *DTNBPI* is also found in the nucleus, where it is reported to regulate transcription factor NF-kappa B activity to promote the expression of matrix metalloproteinase

protein-9 (MMP-9), a matrix metalloproteinase that influences synaptic plasticity and learning and memory, and TNF- α [164]. In mice containing a loss-of-function mutation in *DTNBPI* (*sandy*, *sdyl*), they demonstrate hyperactivity, deficits in spatial learning and memory ability that are indicative of disrupted hippocampal function, and disruption of DA-ergic, glutamatergic, and GABA-ergic transmission in the prefrontal cortex [165–171]. While genetic background does appear to be an important factor in determining whether specific schizophrenia-related phenotypes are reported for the *sdyl* mouse, memory impairment is a consistent phenotypic trait of *DTNBPI*-deficient mice irrespective of the mouse strain adopted [166, 172, 173].

Clinical studies provide some evidence indicating potentially significant associations between *DTNBPI* gene variation and the impact of adverse environmental risk factors on risk to develop schizophrenia [174, 175]. A study which examined potential interactions between *DTNBPI* variation and serious obstetric complications in a cohort of schizophrenia patients reported that the interaction of both factors influenced risk for schizophrenia [174]. It is also suggested that a common underlying molecular defect involving *DTNBPI* contribution to the development of anxiety and stress-related disorders may involve changes in glutamatergic neurotransmission or DA-ergic function [175]. Indeed, characterisation of the behavioural phenotype of the *sdyl* mouse revealed enhanced anxiety in these mutants, as indicated by a reduced habituation to novelty, reduced locomotor activity and time spent in the center of an open field test, and fewer open arm entries in the elevated plus maze test [166, 176]. It is possible, therefore, that *DTNBPI* mutation directly or indirectly affects neuronal circuitry subserving anxiety behaviours and stress responsivity, meriting further examination of potential interactions between stress-related environmental risk factors in schizophrenia and *DTNBPI* gene abnormalities.

The timing of environmental insults during development and specific genetic vulnerability are important considerations in determining susceptibility to neurodevelopmental disorders and could differentially affect the degree to which *DTNBPI* mutations impact on structural and functional properties of neuronal cells, circuit connectivity, and overt behavioural phenotypes such as cognition, anxiety, and affective behaviour, leading to heterogeneous clinical phenotypes in schizophrenia [2, 25]. Evidence indicates that endogenous levels of the dysbindin protein in the mouse brain are higher during embryonic and early postnatal ages [177] suggesting adverse experiences during these vulnerable periods are more likely to affect the developmental course of dysbindin protein expression than those experienced during later stages of development. These findings highlight the critical nature of the temporal expression of *DTNBPI* in the brain and suggest that environmental factors experienced in early postnatal life and in adolescence may significantly impact on the trajectory of brain development and susceptibility to schizophrenia in those with *DTNBPI*-related genetic vulnerability.

9.2. *SNAP-25*. *Synaptosomal-associated protein of 25 kDa* (*SNAP-25*) is a gene associated with both synaptic transmission [178] and increased risk for schizophrenia [179, 180]. Mice containing a point mutation in the *SNAP-25* gene display several schizophrenia-associated endophenotypes including hyperactivity and increased behavioural sensitivity to psychostimulants, which are both mediated through DA D2 receptor activation [181, 182]. *SNAP-25* mutants were demonstrated to be particularly sensitive to the disruptive effects of variable prenatal stress on social novelty preference [183]. In the same study, both the point mutation and variable prenatal stress independently produced disruption of PPI. In a recent study, prenatal exposure to nicotine throughout gestation and early perinatal development in mice with partial loss of function of *SNAP-25* resulted in increased hyperactivity, social interaction deficits, and deficits in long-term depression, which are paralleled by changes in the affinity of the DA D2 receptor [184].

9.3. *BDNF*. Brain-derived neurotrophic factor (*BDNF*) is implicated in diverse neurodevelopmental processes, including neuronal differentiation and survival, and plasticity, and may be important to the pathophysiology of schizophrenia [162, 185]. Theleritis et al. [186] demonstrated that *BDNF* genotype is related to childhood trauma but not to cognitive deficits in first episode schizophrenia. Exposure of pregnant mice to restraint stress was associated with increased *BDNF* expression in the frontal cortex and hippocampus of adult offspring [187]. A recent study evaluated the interaction between prolonged adolescent exposure to escalating doses of methamphetamine and heterozygous disruption of *BDNF* in mice and demonstrated that decreased *BDNF* expression may alter sensitivity to psychostimulant exposure at important developmental periods [188]. Methamphetamine-treated wild-type mice, but not *BDNF* heterozygous mice, showed locomotor sensitization to acute 3 mg/kg D-amphetamine, and this study also demonstrated increased sensitivity to amphetamine-induced disruption of PPI in *BDNF* heterozygotes [189].

9.4. *RELN*. Reelin is a protein that is involved in brain development and synaptic plasticity; Reelin-mediated signalling pathway dysfunction has been linked with the pathophysiology of schizophrenia [190, 191]. *Reeler* is an autosomal recessive mutant mouse containing a mutation in the *RELN* gene, and several studies have examined the phenotypic consequences of interaction between early life adversity and the heterozygous *reeler* mouse phenotype. Interestingly, *reeler* mutants who were prenatally exposed to the neurotoxin chlorpyrifos [192] or early maternal separation [193] demonstrated a reversal of genotypic deficits across a number of schizophrenia-relevant endophenotypes; these included abnormalities in ultrasonic vocalisations and exploratory behaviour, as well as social interaction [193]. Neither chlorpyrifos exposure nor maternal separation alone exerted any effects on offspring behaviour. A recent study examined the phenotypic consequences of prenatal hypoxia on schizophrenia-related phenotypes in heterozygous *reeler* mice [194]. Exposure to prenatal hypoxia at embryonic day 17

(E17) was associated with a genotype-independent increase in anxiety (measured in the open-field test). No effect of genotype on PPI was observed, but a small treatment-related increase in PPI across both genotypes was reported [194]. *RELN* genotype \times prenatal hypoxia interaction was found in relation to frontal cortex volume, which was increased in wildtypes, but the genotypic increase in *RELN* mutants was decreased following prenatal hypoxia exposure. A selective reduction in glucocorticoid receptor protein levels in the hippocampus of stressed *RELN* mutants was also observed.

10. Discussion

The current review provides a summary of findings arising from the growing body of research on the generation of animal models of schizophrenia based on the interaction of genetic mutations and well-characterised environmental factors ([28, 49, 195]; see Tables 1 and 2 for summary of $G \times E$ findings related to selected schizophrenia-associated genes). These findings support the proposed “multihit” diathesis-stress model, whereby vulnerability to schizophrenia involves both the independent contribution and synergistic convergence of temporally sensitive biological and environmental factors across development. Identification of biological and environmental influences across critical developmental periods and the mechanistic basis for their interaction may eventually result in enhanced identification of schizophrenia risk and the development of suitable preventative strategies.

A number of caveats and methodological considerations arise from our review of preclinical $G \times E$ models relevant to schizophrenia. Firstly, the heuristic value of a $G \times E$ model depends upon the level of construct validity possessed by the experimental model of the environmental stressor. Translation of epidemiologically appropriate environmental factors into current animal models of $G \times E$ interactions constitutes a particular challenge for models of $G \times E$ interplay in schizophrenia [196]. Secondly, it has to be noted that the majority of the studies outlined above have been conducted using rodent models involving a single gene mutation, while schizophrenia is a polygenic disorder [5]. Thirdly, much of the evidence outlined in the preceding sections is essentially descriptive, or the studies cited have focused on a limited number of molecular markers; more detailed molecular interrogation of phenotypic effects, at different time points, is required. In particular, neural circuits in animal models of $G \times E$ interactions will need to be examined with respect to behavioural changes, with a particular attention to the pathological trajectory from early development to the emergence and expression of the specified disease-relevant endophenotypes in adulthood [5]. These mechanistic studies will provide a solid basis for the development and evaluation of targeted preventative or rescue strategies. Lastly, several of the $G \times E$ models discussed have demonstrated that the effects of coexposure to a genetic mutation and an environmental stressor can result in modification of the phenotypic effects of one factor or the other but may also produce phenotypic effects, both protective and adverse, which may not be observed following exposure to any one factor alone [28].

It has been suggested that genetic risk to develop a psychotic disorder may be expressed as altered responsivity to everyday stressful situations [197], such that idiopathic responsivity to stressors may be an important determinant of induction of psychosis. At a phenotypic level, both the human genetic and preclinical $G \times E$ data related to schizophrenia have highlighted the importance of incorporating behavioural and physiological measures of stress responsivity in any phenotyping strategy. Both streams of evidence have clearly shown that it represents a modulating trait which might increase risk for schizophrenia [198, 199] and modulate the expression or severity of schizophrenia-relevant endophenotypes in preclinical $G \times E$ models (e.g., [24]).

As evident in the above description of $G \times E$ interaction in relevant mutant models, sex-specific effects are commonly observed, even allowing for the limited number of studies which have examined such effects in both sexes. Gender differences in schizophrenia have been noted across such domains as symptomatology and course of illness. Males show lower premorbid functioning, earlier age of onset, more severe cognitive deficits, and poorer prognosis at an earlier age of onset, and a poorer course of illness [200, 201]. There is sufficient evidence to conclude that independent and interactive effects of genetic and environmental manipulations on behavioural indices can differ between the sexes. Therefore, there is a requirement for $G \times E$ models to be validated for both sexes.

Despite the difficulty in interpreting the evidence for first- and second-order interactions arising from multifactorial $G \times E$ studies conducted in nonhumans, some authors have proposed common biological mechanisms or processes which might underlie such interactions [5]. One such mechanism is a disturbance in glutamatergic function, which may be related to dysfunction of parvalbumin-positive interneurons in the cerebral cortex and hippocampus, which are sensitive to alterations in NMDA-type glutamate receptors [202]. One of the common findings in both animal models and postmortem tissue from patients with schizophrenia is a reduction of mRNA or protein levels of the calcium-binding protein parvalbumin in cortical fast-spiking (FS) interneurons. Both preclinical genetic and environmentally based models using schizophrenia risk genes or stressors, respectively, have consistently observed a decreased number or impaired function of parvalbumin-positive interneurons in the hippocampus or cortex [91, 203]. A different model has suggested that genetic risk factors interact with social environmental risk factors (including early life adversity and psychosocial stress) to impact on the DA system, increasing its response to environmental stressors and to the abuse of drugs such as cannabis and psychostimulants [204, 205]. There are various strands of evidence to support this theory, including the well-characterised impact of acute and long-term exposure to stress and drugs of abuse on mesolimbic DA-ergic pathway dysfunction, and the fact that many of the genetic risk factors implicated in schizophrenia are associated with underlying alterations in the DA system [206]. Mesolimbic DA-ergic dysregulation is posited to be a fluid and dynamic process that may be reactive to acute and chronic stressors, including early brain insult, prolonged exposure to

TABLE 1: Summary of evidence for gene, environment, and gene × environment effects in mutant models for selected genes associated with schizophrenia.

Gene target	Environmental exposure	Reference(s)	Genetic manipulation	Impact on schizophrenia-relevant behavioural endophenotypes	Gene × environment	Use of preventative or rescue strategy
<i>NRG1</i>	Prenatal Poly I:C	[92]	Decreased social novelty preference and PPI; sex-specific (females only) decrease in working memory	Disruption of working memory and PPI	Decreased sociability in Poly I:C × WT mice only; sex-specific decrease in alternation (i.e., working memory) following Poly I:C treatment was attenuated in female <i>NRG1</i> mutants	—
<i>NRG1</i>	Acute Δ-9 THC during adulthood	[128, 129]	Increased novelty-induced activity; decreased anxiety in the elevated plus maze and light-dark test; increased <i>c-fos</i> expression in the lateral septum and nucleus accumbens	Decreased novelty-induced activity; increased anxiety in the elevated plus maze; enhanced PPI; decreased social interaction; increased <i>c-fos</i> expression in the dorsolateral part of the bed nucleus of the stria terminalis and central nucleus of the amygdala	Increased sensitivity to locomotor suppressant effects of THC in <i>NRG1</i> mutants; greater PPI enhancement in <i>NRG1</i> mutants; greater increase in <i>c-fos</i> expression in the dorsolateral part of the bed nucleus of the stria terminalis and central nucleus of the amygdala, and paraventricular nucleus of the hypothalamus in <i>NRG1</i> mutants	—
<i>NRG1</i>	Subchronic CP 55,940 [CB1R agonist] during adulthood	[131]	Increased novelty-induced activity	Decreased novelty-induced activity; increased anxiety in elevated plus maze and open field	Increased tolerance to CP55,940-induced anxiolytic and locomotor suppressant effects in <i>NRG1</i> mutants; increased <i>c-fos</i> expression in lateral septum in treated <i>NRG1</i> mutants	—
<i>NRG1</i>	Subchronic Δ-9-THC during adolescence	[132]	Increased novelty-induced activity	Decreased novelty-induced activity	Decreased anxiogenic effects of THC in <i>NRG1</i> mutants; decreased social investigative behaviours in WT only; disruption of PPI in THC-treated <i>NRG1</i> mutants	—
<i>NRG1</i>	Subchronic cannabidiol during adulthood	[136]	Increased novelty-induced activity; disrupted PPI; decreased 5-HT _{2a} receptor binding in substantia nigra	Enhanced PPI after acute cannabidiol; increased social interaction following chronic cannabidiol	Decreased sensitivity to anxiolytic effects of cannabidiol in mutants; selective enhancement of social interaction and PPI in <i>NRG1</i> mutants; selective enhancement of GABA _A receptor binding in the granular retrosplenial cortex of <i>NRG1</i> mutants and reduction of 5-HT _{2a} receptor binding in the substantia nigra of WT	—

TABLE 1: Continued.

Gene target	Environmental exposure	Reference(s)	Genetic manipulation	Impact on schizophrenia-relevant behavioural endophenotypes	Gene × environment	Use of preventative or rescue strategy
<i>NRG1</i>	Subchronic Δ -9 THC during adolescence	[133]	Altered expression of proteins involved in vesicular release of neurotransmitters, 5-HT neurotransmission, and growth factor expression	Environmental manipulation	Altered expression of proteins implicated in NMDA-mediated glutamatergic neurotransmission	—
			Increased novelty-induced activity; decreased social novelty preference; PPI disruption; decreased anxiety	Reduced hippocampal expression of heat shock proteins and oxidative stress	Gene × environment	Selective decrease in anxiety and working memory in stressed <i>NRG1</i> mutants; protective effect of <i>NRG1</i> genotype on disruption of sucrose preference following social defeat
<i>NRG1</i>	Social defeat during adolescence	[86]	—	—	—	—
<i>NRG1</i>	Chronic restraint stress during adolescence	[153]	—	Increased NMDA receptor binding in ventral part of the lateral septum and dentate gyrus	PPI disruption in <i>NRG1</i> only following chronic stress exposure; altered patterns of NMDA receptor binding in infralimbic subregion of medial prefrontal cortex and dentate gyrus; decreased corticosterone levels, as well as increased apical dendritic spine density and decreased apical dendritic lengths and complexity in layer II/III pyramidal neurons of the medial prefrontal cortex	—
			—	—	Increase in anxiety in elevated plus maze and increased immobility in forced swim test in <i>DISC1</i> mutants; decreased social interaction in challenged <i>DISC1</i> offspring; decreased linear spine density on dendrites of granule cells of the dentate gyrus in <i>DISC1</i> mutants only; opposite effects on lateral ventricle volume (increased in WT, decreased in mutants)	—
<i>DISC1</i>	Prenatal Poly I:C	[50]	Enlargement of the lateral ventricles	Increased anxiety in open field; decreased volume of amygdala and left/right periaqueductal grey; decrease in linear density of spines in pyramidal neurons of the CA1 region	—	—

TABLE 1: Continued.

Gene target	Environmental exposure	Reference(s)	Genetic manipulation	Impact on schizophrenia-relevant behavioural endophenotypes	Gene × environment	Use of preventative or rescue strategy
<i>DISC1</i>	Prenatal Poly I:C	[104]	Decreased PPI in <i>DISC1</i> Q31L mutant; decreased LI and social affiliative behaviour in <i>DISC1</i> Li00P line	Decreased PPI and LI; disruption of spatial discrimination and object exploration	More prominent PPI and LI deficits in Li00P mutants; impaired working memory and sociability in challenged <i>DISC1</i> offspring; increase of Poly I:C-induced increase in IL-6 in brains of <i>DISC1</i> mutants	Coadministration of IL-6 antagonist with Poly I:C reversed Poly I:C-related deficits in mutants and controls
<i>DISC1</i>	Neonatal Poly I:C	[105, 106]	—	—	Selective deficits in short-term memory and object recognition memory in <i>DISC1</i> mutants; increased behavioural sensitivity to MK-801 in <i>DISC1</i> mice exposed to Poly I:C; selective decrease in parvalbumin-positive interneurons in the medial prefrontal cortex	Cognitive deficits in Poly I:C-treated <i>DISC1</i> mutants improved by clozapine while haloperidol had no effect; clozapine suppressed the augmentation of MK-801-induced hyperactivity
<i>DISC1</i>	Prenatal lead exposure	[107]	Enlargement of lateral ventricles; decreased anxiety in open field	Increased anxiety in open field; increased anxiety in elevated plus maze; increased MX-801 responsiveness; decreased PPI; enlargement of lateral ventricles	Heightened responsiveness to the NMDAR antagonist MK-801 and increased PPI disruption in female <i>DISC1</i> mice; synergistic decrease in exploratory activity and synergistic increase in lateral ventricular volume in <i>DISC1</i> mutants	Systemic administration of D-serine, a coagonist at the NMDA receptor, reversed PPI deficits in female lead-exposed mutants
<i>DISC1</i>	Subchronic Δ -9 THC during adolescence	[137]	Decrease in contextual fear memory; decreased synaptic CB1R expression in the prefrontal cortex, hippocampus, and amygdala	Decrease in synaptic CB1R expression in the prefrontal cortex, hippocampus, and amygdala	Disruption in cue-dependent fear memory	—
<i>DISC1</i>	Social defeat during adulthood	[154]	Decreased PPI in <i>DISC1</i> Li00P; impaired LI in Li00P and <i>DISC1</i> Q31L; decreased sociability and social novelty in Q31L mutants	Increased immobility in forced swim test; decreased sucrose intake in the sucrose consumption test	Decrease in exploratory activity and sociability and social novelty in Li00P; increase in anxiety in the elevated plus maze in Li00P but not Q31L mutants exposed to social defeat	—

TABLE 1: Continued.

Gene target	Environmental exposure	Reference(s)	Genetic manipulation	Environmental behavioural endophenotypes	Gene × environment	Use of preventative or rescue strategy
<i>DISC1</i>	Prolonged social isolation during adolescence	[51, 155]	—	—	PPI disruption, forced swim immobility, and methamphetamine-induced locomotion, in isolated <i>DISC1</i> mutants; decreased tyrosine hydroxylase expression, total tissue DA levels, and DA in the frontal cortex; increased DA release in the nucleus accumbens; altered DNA methylation of <i>tyrosine hydroxylase</i> , <i>BDNF</i> , and <i>FK506 binding protein 5</i> genes	RU-486 normalized basal and methamphetamine-induced extracellular DA, tyrosine hydroxylase, and DA D2 receptor levels in G × E model; RU-486 also reversed PPI, forced swim test deficits, and changes in amphetamine-induced activity in this model
<i>COMT</i>	Subchronic Δ -9 THC during adolescence	[123]	Improved spatial working memory in <i>COMT</i> KO males	Decreased object recognition, social novelty preference, and anxiety	Increased hyperactivity and greater disruption of working memory in THC-treated <i>COMT</i> KO mice	—
<i>COMT</i>	Subchronic Win 55,212 [CBIR agonist] during adolescence	[143]	—	Decreased social novelty preference; decreased anxiety in the light-dark test	Selective disruption of PPI in cannabinoid-treated <i>COMT</i> mutants; decreased sensitivity to disruptive effects on sociability in mutants relative to WT	—
<i>COMT</i>	Subchronic Δ -9 THC during adolescence	[144]	Increased CBIR intensity in the prefrontal cortex; decreased CBIR intensity in the hippocampus; parvalbumin cell size decreased in <i>COMT</i> heterozygotes	Decreased cell density in the VTA	Decreased parvalbumin cell intensity in the prefrontal cortex; decreased DA cell size in VTA; increased CBIR intensity in hippocampus of THC-treated <i>COMT</i> mutants	—

BDNF, brain-derived neurotrophic factor; CBIR, cannabinoid receptor 1; *COMT*, catechol-O-methyltransferase; DA, dopamine; Δ -9 THC, delta-9-tetrahydrocannabinol; *DISC1*, disrupted in schizophrenia 1; GABA_A, gamma-aminobutyric acid type A receptor; IL-6, interleukin 6; KO, knockout; LI, latent inhibition; NMDA receptor, N-methyl-D-aspartate receptor; NRG1, neuregulin-1; PPI, prepulse inhibition; 5-HT_{2A}, serotonin 2_A receptor; VTA, ventral tegmental area.

TABLE 2: Summary of evidence for gene, environment, and gene \times environment effects in mutant models for selected genes associated with schizophrenia.

Gene target	Environmental exposure	Reference(s)	Impact on schizophrenia-relevant behavioural endophenotypes			Use of preventative or rescue strategy
			Genetic manipulation	Environmental manipulation	Gene \times environment	
<i>Nurr1</i>	Prenatal Poly I:C	[110]	Increased novelty-induced activity; decreased PPI, reduction in tyrosine hydroxylase-positive cells in the substantia nigra	Increased novelty-induced activity; decreased PPI; spatial working memory deficits; increase in tyrosine hydroxylase-positive cells in the VTA	Additive effects on novelty-induced hyperactivity; synergistic reduction in attentional shifting and sustained attention; decrease in DA D2 receptor immunoreactivity in the nucleus accumbens	—
<i>Snap-25</i>	Variable prenatal stress	[183]	Decreased PPI in the <i>blind-drunk</i> point mutant	PPI disruption	Decreased social novelty preference	Clozapine and haloperidol (to a lesser extent) reversal of PPI deficits was most pronounced in G \times E group
<i>Snap-25</i>	Prenatal nicotine exposure	[184]	Increased novelty-induced activity and decreased social interaction	—	More pronounced novelty-induced hyperactivity and greater disruption of social interaction; deficits in DA D2 receptor-dependent induction of long-term synaptic depression	—
<i>BDNF</i>	Chronic methamphetamine exposure	[188]	—	Locomotor sensitisation and increased entropy	Decreased locomotor sensitisation and entropy in <i>BDNF</i> heterozygotes	—
<i>BDNF</i>	Chronic methamphetamine exposure	[189]	Decreased PPI and increased acoustic startle reactivity in <i>BDNF</i> heterozygotes	Locomotor sensitisation; increased sensitivity to MK-801 and amphetamine-induced PPI disruption	Increased sensitivity to amphetamine-induced PPI disruption in preexposed <i>BDNF</i> heterozygotes	—
<i>RELN</i>	Maternal separation	[193]	Decreased frequency of ultrasonic vocalisations; decreased activity in a novel environment	—	Decreased sensitivity to disruptive effects of maternal separation in heterozygous <i>RELN</i> mutants	—
<i>RELN</i>	Prenatal exposure to the pesticide chlorpyrifos Maternal separation	[192]	Decreased frequency of ultrasonic vocalisations	—	Prenatal chlorpyrifos: selective increase in ultrasonic vocalisation in <i>RELN</i> mutants; disrupted behavioural response to acute scopolamine Maternal separation: decreased social motivation in WT but not <i>RELN</i> mutants	—

TABLE 2: Continued.

Gene target	Environmental exposure	Reference(s)	Impact on schizophrenia-relevant behavioural endophenotypes			Use of preventative or rescue strategy
			Genetic manipulation	Environmental manipulation	Gene × environment	
<i>RELN</i>	Prenatal hypoxia	[194]	Increase in frontal cortex volume in <i>RELN</i> mutants	Reduction in glucocorticoid receptor protein levels in frontal cortex	Increase in frontal cortex volume in WT but opposite effect observed in <i>RELN</i> mutants; selective reduction in glucocorticoid receptor protein levels in hippocampus of <i>RELN</i> mutants; selective changes in brain expression of hypoxia-related proteins in mutants	—

BDNF, brain-derived neurotrophic factor; DA, dopamine; Δ -9 THC, delta-9-tetrahydrocannabinol; NURRI, nuclear receptor related 1 protein; PPI, prepulse inhibition; *RELN*, reelin; SNAP-25, synaptosome associated protein 25 kDa; VTA, ventral tegmental area; WT, wildtype.

drugs of abuse, and psychosocial stress, across the lifespan of the individual. Another theory places a greater emphasis on the convergence of genetic and environmental factors upon regulation of synaptic plasticity and function, as well as the stabilisation of cortical microcircuitry [42, 207]. It has been observed that intact synaptic function depends on a large number of molecular pathways which will be affected by several environmental factors throughout brain development. Additionally, stress-associated signalling cascades are well known to modulate the development and maintenance of synaptic connectivity [5].

What existing animal studies of $G \times E$ interactions relevant to schizophrenia highlight is that developing valid multifactorial models which are amenable to investigations not yet possible in clinical studies will become increasingly important in determining the mechanisms underlying convergence of genetic and environmental risk factors and their interaction.

Competing Interests

The authors declare that they have no competing interests.

References

- [1] A. S. Brown, "Prenatal infection as a risk factor for schizophrenia," *Schizophrenia Bulletin*, vol. 32, no. 2, pp. 200–202, 2006.
- [2] A. S. Brown, "The environment and susceptibility to schizophrenia," *Progress in Neurobiology*, vol. 93, no. 1, pp. 23–58, 2011.
- [3] P. D. Harvey, A. P. Wingo, K. E. Burdick, and R. J. Baldessarini, "Cognition and disability in bipolar disorder: lessons from schizophrenia research," *Bipolar Disorders*, vol. 12, no. 4, pp. 364–375, 2010.
- [4] J. L. Waddington, R. J. Hennessy, C. M. P. O'Tuathaigh et al., "Schizophrenia and the lifetime trajectory of psychotic illness: developmental neuroscience and pathobiology, redux," in *The Origins of Schizophrenia*, A. S. Brown and P. H. Patterson, Eds., pp. 3–21, Columbia University Press, New York, NY, USA, 2012.
- [5] M. J. Owen, A. Sawa, and P. B. Mortensen, "Schizophrenia," *The Lancet*, vol. 388, no. 10039, pp. 86–97, 2016.
- [6] A. Gustavsson, M. Svensson, F. Jacobi et al., "Cost of disorders of the brain in Europe 2010," *European Neuropsychopharmacology*, vol. 21, no. 10, pp. 718–779, 2011.
- [7] H. U. Wittchen, F. Jacobi, J. Rehm et al., "The size and burden of mental disorders and other disorders of the brain in Europe 2010," *European Neuropsychopharmacology*, vol. 21, no. 9, pp. 655–679, 2011.
- [8] S. Leucht and S. Heres, "Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia," *Journal of Clinical Psychiatry*, vol. 67, no. 5, pp. 3–8, 2006.
- [9] P. J. Harrison, "Recent genetic findings in schizophrenia and their therapeutic relevance," *Journal of Psychopharmacology*, vol. 29, no. 2, pp. 85–96, 2015.
- [10] J. L. Rapoport, J. N. Giedd, and N. Gogtay, "Neurodevelopmental model of schizophrenia: update 2012," *Molecular Psychiatry*, vol. 17, no. 12, pp. 1228–1238, 2012.
- [11] J. Gratten, N. R. Wray, M. C. Keller, and P. M. Visscher, "Large-scale genomics unveils the genetic architecture of psychiatric disorders," *Nature Neuroscience*, vol. 17, no. 6, pp. 782–790, 2014.
- [12] M. Burmeister, "Basic concepts in the study of diseases with complex genetics," *Biological Psychiatry*, vol. 45, no. 5, pp. 522–532, 1999.
- [13] M. Burmeister, M. G. McInnis, and S. Zöllner, "Psychiatric genetics: progress amid controversy," *Nature Reviews Genetics*, vol. 9, no. 7, pp. 527–540, 2008.
- [14] S. Zammit, M. J. Owen, and G. Lewis, "Misconceptions about gene-environment interactions in psychiatry," *Evidence-Based Mental Health*, vol. 13, no. 3, pp. 65–68, 2010.
- [15] M. R. Munafò, S. Zammit, and J. Flint, "Practitioner Review: a critical perspective on gene-environment interaction models—what impact should they have on clinical perceptions and practice?" *Journal of Child Psychology and Psychiatry and Allied Disciplines*, vol. 55, no. 10, pp. 1092–1101, 2014.
- [16] R. A. Shih, P. L. Belmonte, and P. P. Zandi, "A review of the evidence from family, twin and adoption studies for a genetic

- contribution to adult psychiatric disorders," *International Review of Psychiatry*, vol. 16, no. 4, pp. 260–283, 2004.
- [17] C. A. Prescott and I. I. Gottesman, "Genetically mediated vulnerability to schizophrenia," *Psychiatric Clinics of North America*, vol. 16, no. 2, pp. 245–267, 1993.
- [18] M. S. Keshavan, "Development, disease and degeneration in schizophrenia: a unitary pathophysiological model," *Journal of Psychiatric Research*, vol. 33, no. 6, pp. 513–521, 1999.
- [19] S. Tosato, P. Dazzan, and D. Collier, "Association between the neuregulin 1 gene and schizophrenia: a systematic review," *Schizophrenia Bulletin*, vol. 31, no. 3, pp. 613–617, 2005.
- [20] M. J. Owen, "Implications of genetic findings for understanding schizophrenia," *Schizophrenia Bulletin*, vol. 38, no. 5, pp. 904–907, 2012.
- [21] C. A. Ross, R. L. Margolis, S. A. J. Reading, M. Pletnikov, and J. T. Coyle, "Neurobiology of schizophrenia," *Neuron*, vol. 52, no. 1, pp. 139–153, 2006.
- [22] M. C. O'Donovan, N. J. Craddock, and M. J. Owen, "Genetics of psychosis: insights from views across the genome," *Human Genetics*, vol. 126, no. 1, pp. 3–12, 2009.
- [23] D. S. Rudd, M. Axelsen, E. A. Epping, N. C. Andreasen, and T. H. Wassink, "A genome-wide CNV analysis of schizophrenia reveals a potential role for a multiple-hit model," *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, vol. 165, no. 8, pp. 619–626, 2014.
- [24] T. Karl, "Neuregulin 1: a prime candidate for research into gene-environment interactions in schizophrenia? Insights from genetic rodent models," *Frontiers in Behavioral Neuroscience*, vol. 7, article 106, 2013.
- [25] G. Kannan, A. Sawa, and M. V. Pletnikov, "Mouse models of gene-environment interactions in schizophrenia," *Neurobiology of Disease*, vol. 57, pp. 5–11, 2013.
- [26] C. M. O'Tuathaigh and J. L. Waddington, "Closing the translational gap between mutant mouse models and the clinical reality of psychotic illness," *Neuroscience and Biobehavioral Reviews*, vol. 58, pp. 19–35, 2015.
- [27] V. Labrie, S. Pai, and A. Petronis, "Epigenetics of major psychosis: progress, problems and perspectives," *Trends in Genetics*, vol. 28, no. 9, pp. 427–435, 2012.
- [28] Y. Ayhan, R. McFarland, and M. V. Pletnikov, "Animal models of gene-environment interaction in schizophrenia: a dimensional perspective," *Progress in Neurobiology*, vol. 136, pp. 1–27, 2016.
- [29] D. Malaspina, "Paternal factors and schizophrenia risk: de novo mutations and imprinting," *Schizophrenia Bulletin*, vol. 27, no. 3, pp. 379–393, 2001.
- [30] A. Reichenberg, R. Gross, S. Sandin, and E. S. Susser, "Advancing paternal and maternal age are both important for autism risk," *American Journal of Public Health*, vol. 100, no. 5, pp. 772–773, 2010.
- [31] A. Kong, M. L. Frigge, G. Masson et al., "Rate of de novo mutations and the importance of father's age to disease risk," *Nature*, vol. 488, no. 7412, pp. 471–475, 2012.
- [32] M. C. Perrin, A. S. Brown, and D. Malaspina, "Aberrant epigenetic regulation could explain the relationship of paternal age to schizophrenia," *Schizophrenia Bulletin*, vol. 33, no. 6, pp. 1270–1273, 2007.
- [33] R. G. Smith, A. Reichenberg, R. L. Kember et al., "Advanced paternal age is associated with altered DNA methylation at brain-expressed imprinted loci in inbred mice: implications for neuropsychiatric disease," *Molecular Psychiatry*, vol. 18, no. 6, pp. 635–636, 2013.
- [34] P. F. Sullivan, K. S. Kendler, and M. C. Neale, "Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies," *Archives of General Psychiatry*, vol. 60, no. 12, pp. 1187–1192, 2003.
- [35] International Schizophrenia Consortium, "Rare chromosomal deletions and duplications increase risk of schizophrenia," *Nature*, vol. 455, pp. 237–241, 2008.
- [36] H. Stefansson, D. Rujescu, S. Cichon et al., "Large recurrent microdeletions associated with schizophrenia," *Nature*, vol. 455, pp. 232–236, 2008.
- [37] G. Kirov, D. Rujescu, A. Ingason, D. A. Collier, M. C. O'Donovan, and M. J. Owen, "Neurexin 1 (NRXN1) deletions in schizophrenia," *Schizophrenia Bulletin*, vol. 35, no. 5, pp. 851–854, 2009.
- [38] P. V. Gejman, A. R. Sanders, and K. S. Kendler, "Genetics of schizophrenia: new findings and challenges," *Annual Review of Genomics and Human Genetics*, vol. 12, pp. 121–144, 2011.
- [39] Schizophrenia Working Group of the Psychiatric Genomics Consortium, "Biological insights from 108 schizophrenia-associated genetic loci," *Nature*, vol. 511, pp. 421–427, 2014.
- [40] C. L. Winchester, J. A. Pratt, and B. J. Morris, "Risk genes for schizophrenia: translational opportunities for drug discovery," *Pharmacology and Therapeutics*, vol. 143, no. 1, pp. 34–50, 2014.
- [41] S. M. Purcell, J. L. Moran, M. Fromer et al., "A polygenic burden of rare disruptive mutations in schizophrenia," *Nature*, vol. 506, no. 7487, pp. 185–190, 2014.
- [42] J. Hall, S. Trent, K. L. Thomas, M. C. O'Donovan, and M. J. Owen, "Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity," *Biological Psychiatry*, vol. 77, no. 1, pp. 52–58, 2015.
- [43] Cross-Disorder Group of the Psychiatric Genomics Consortium, "Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs," *Nature Genetics*, vol. 45, pp. 984–994, 2013.
- [44] D. M. Ruderfer, A. H. Fanous, S. Ripke et al., "Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia," *Molecular Psychiatry*, vol. 19, no. 9, pp. 1017–1024, 2014.
- [45] S. A. McCarroll, G. Feng, and S. E. Hyman, "Genome-scale neurogenetics: methodology and meaning," *Nature Neuroscience*, vol. 17, no. 6, pp. 756–763, 2014.
- [46] F. Cirulli, N. Francia, A. Berry, L. Aloe, E. Alleva, and S. J. Suomi, "Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates," *Neuroscience and Biobehavioral Reviews*, vol. 33, no. 4, pp. 573–585, 2009.
- [47] E. J. Nestler and S. E. Hyman, "Animal models of neuropsychiatric disorders," *Nature Neuroscience*, vol. 13, no. 10, pp. 1161–1169, 2010.
- [48] J. van Os, G. Kenis, and B. P. F. Rutten, "The environment and schizophrenia," *Nature*, vol. 468, no. 7321, pp. 203–212, 2010.
- [49] L. Gray and A. J. Hannan, "Dissecting cause and effect in the pathogenesis of psychiatric disorders: genes, environment and behaviour," *Current Molecular Medicine*, vol. 7, no. 5, pp. 470–478, 2007.
- [50] B. Abazyan, J. Nomura, G. Kannan et al., "Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology," *Biological Psychiatry*, vol. 68, no. 12, pp. 1172–1181, 2010.
- [51] M. Niwa, R. S. Lee, T. Tanaka, K. Okada, S. Kano, and A. Sawa, "A critical period of vulnerability to adolescent stress: epigenetic

- mediators in mesocortical dopaminergic neurons,” *Human Molecular Genetics*, vol. 25, no. 7, pp. 1370–1381, 2016.
- [52] T. D. Cannon, T. G. M. Van Erp, C. E. Bearden et al., “Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions,” *Schizophrenia Bulletin*, vol. 29, no. 4, pp. 653–669, 2003.
- [53] C. M. O’Tuathaigh, L. Desbonnet, P. M. Moran, and J. L. Waddington, “Susceptibility genes for schizophrenia: mutant models, endophenotypes and psychobiology,” *Current Topics in Behavioural Neuroscience*, vol. 12, pp. 209–250, 2012.
- [54] D. Braff, N. J. Schork, and I. I. Gottesman, “Endophenotyping schizophrenia,” *American Journal of Psychiatry*, vol. 164, no. 5, pp. 705–707, 2007.
- [55] B. N. Cuthbert and T. R. Insel, “Toward the future of psychiatric diagnosis: the seven pillars of RDoC,” *BMC Medicine*, vol. 11, article 126, 2013.
- [56] B. D. Kelly, E. O’Callaghan, J. L. Waddington et al., “Schizophrenia and the city: a review of literature and prospective study of psychosis and urbanicity in Ireland,” *Schizophrenia Research*, vol. 116, no. 1, pp. 75–89, 2010.
- [57] P. Casadio, C. Fernandes, R. M. Murray, and M. Di Forti, “Cannabis use in young people: the risk for schizophrenia,” *Neuroscience and Biobehavioral Reviews*, vol. 35, no. 8, pp. 1779–1787, 2011.
- [58] J. J. McGrath, M. R. Pemberton, J. L. Welham, and R. M. Murray, “Schizophrenia and the influenza epidemics of 1954, 1957 and 1959: a southern hemisphere study,” *Schizophrenia Research*, vol. 14, no. 1, pp. 1–8, 1994.
- [59] M. Cannon, D. Cotter, V. P. Coffey et al., “Prenatal exposure to the 1957 influenza epidemic and adult schizophrenia: a follow-up study,” *British Journal of Psychiatry*, vol. 168, pp. 368–371, 1996.
- [60] P. B. Mortensen, C. B. Pedersen, T. Westergaard et al., “Effects of family history and place and season of birth on the risk of schizophrenia,” *The New England Journal of Medicine*, vol. 340, no. 8, pp. 603–608, 1999.
- [61] S. L. Buka, T. D. Cannon, E. F. Torrey, and R. H. Yolken, “Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring,” *Biological Psychiatry*, vol. 63, no. 8, pp. 809–815, 2008.
- [62] A. S. Brown and E. J. Derkits, “Prenatal infection and schizophrenia: a review of epidemiologic and translational studies,” *The American Journal of Psychiatry*, vol. 167, no. 3, pp. 261–280, 2010.
- [63] U. Meyer, J. Feldon, M. Schedlowski, and B. K. Yee, “Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia,” *Neuroscience and Biobehavioral Reviews*, vol. 29, no. 6, pp. 913–947, 2005.
- [64] U. Meyer, J. Feldon, M. Schedlowski, and B. K. Yee, “Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology,” *Brain, Behavior, and Immunity*, vol. 20, no. 4, pp. 378–388, 2006.
- [65] U. Meyer, P. J. Murray, A. Urwyler, B. K. Yee, M. Schedlowski, and J. Feldon, “Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling,” *Molecular Psychiatry*, vol. 13, no. 2, pp. 208–221, 2008.
- [66] B. K. Bitanirwe, D. Peleg-Raibstein, F. Mouttet, J. Feldon, and U. Meyer, “Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia,” *Neuropsychopharmacology*, vol. 35, no. 12, pp. 2462–2478, 2010.
- [67] L. Shi, S. H. Fatemi, R. W. Sidwell, and P. H. Patterson, “Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring,” *The Journal of Neuroscience*, vol. 23, no. 1, pp. 297–302, 2003.
- [68] U. Meyer, M. Nyffeler, A. Engler et al., “The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology,” *The Journal of Neuroscience*, vol. 26, no. 18, pp. 4752–4762, 2006.
- [69] L. Zuckerman, M. Rehavi, R. Nachman, and I. Weiner, “Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia,” *Neuropsychopharmacology*, vol. 28, no. 10, pp. 1778–1789, 2003.
- [70] S. E. P. Smith, J. Li, K. Garbett, K. Mirnics, and P. H. Patterson, “Maternal immune activation alters fetal brain development through interleukin-6,” *The Journal of Neuroscience*, vol. 27, no. 40, pp. 10695–10702, 2007.
- [71] N. V. Malkova, C. Z. Yu, E. Y. Hsiao, M. J. Moore, and P. H. Patterson, “Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism,” *Brain, Behavior, and Immunity*, vol. 26, no. 4, pp. 607–616, 2012.
- [72] L. Zuckerman and I. Weiner, “Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation,” *Psychopharmacology*, vol. 169, no. 3–4, pp. 308–313, 2003.
- [73] K. Zavitsanou, C. K. Lim, T. Purves-Tyson et al., “Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition,” *Brain, Behavior, and Immunity*, vol. 41, no. 1, pp. 173–181, 2014.
- [74] Y. Piontkewitz, M. Arad, and I. Weiner, “Abnormal trajectories of neurodevelopment and behavior following in utero insult in the rat,” *Biological Psychiatry*, vol. 70, no. 9, pp. 842–851, 2011.
- [75] S. Reisinger, D. Khan, E. Kong, A. Berger, A. Pollak, and D. D. Pollak, “The Poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery,” *Pharmacology and Therapeutics*, vol. 149, pp. 213–226, 2015.
- [76] H. Stefansson, E. Sigurdsson, V. Steinthorsdottir et al., “Neuregulin 1 and susceptibility to schizophrenia,” *American Journal of Human Genetics*, vol. 71, no. 4, pp. 877–892, 2002.
- [77] Y. G. Gong, C. N. Wu, Q. H. Xing, X. Z. Zhao, J. Zhu, and L. He, “A two-method meta-analysis of Neuregulin 1 (NRG1) association and heterogeneity in schizophrenia,” *Schizophrenia Research*, vol. 111, no. 1–3, pp. 109–114, 2009.
- [78] H. C. Loh, P. Y. Tang, S. F. Tee et al., “Neuregulin-1 (NRG-1) and its susceptibility to schizophrenia: a case-control study and meta-analysis,” *Psychiatry Research*, vol. 208, no. 2, pp. 186–188, 2013.
- [79] P. J. Harrison and A. J. Law, “Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology,” *Biological Psychiatry*, vol. 60, no. 2, pp. 132–140, 2006.
- [80] L. Mei and W.-C. Xiong, “Neuregulin 1 in neural development, synaptic plasticity and schizophrenia,” *Nature Reviews Neuroscience*, vol. 9, no. 6, pp. 437–452, 2008.
- [81] K. Hänninen, H. Katila, M. Saarela et al., “Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia,” *European Archives of Psychiatry and Clinical Neuroscience*, vol. 258, no. 1, pp. 10–15, 2007.







- [82] K. Marballi, M. P. Quinones, F. Jimenez et al., "In vivo and in vitro genetic evidence of involvement of neuregulin 1 in immune system dysregulation," *Journal of Molecular Medicine*, vol. 88, no. 11, pp. 1133–1141, 2010.
- [83] T. Kato, A. Kasai, M. Mizuno et al., "Phenotypic characterization of transgenic mice overexpressing neuregulin-1," *PLoS ONE*, vol. 5, no. 12, Article ID e14185, 2010.
- [84] T. Karl, L. Duffy, A. Scimone, R. P. Harvey, and P. R. Schofield, "Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia," *Genes, Brain and Behavior*, vol. 6, no. 7, pp. 677–687, 2007.
- [85] C. M. P. O'Tuathaigh, D. Babovic, G. J. O'Sullivan et al., "Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1," *Neuroscience*, vol. 147, no. 1, pp. 18–27, 2007.
- [86] L. Desbonnet, C. O'Tuathaigh, G. Clarke et al., "Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene \times environment interaction," *Brain, Behavior, and Immunity*, vol. 26, no. 4, pp. 660–671, 2012.
- [87] M. van den Buuse, L. Wischhof, R. X. Lee, S. Martin, and T. Karl, "Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation," *International Journal of Neuropsychopharmacology*, vol. 12, no. 10, pp. 1383–1393, 2009.
- [88] T. Karl, T. H. J. Burne, M. Van den Buuse, and R. Chesworth, "Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?" *Behavioural Brain Research*, vol. 223, no. 2, pp. 336–341, 2011.
- [89] M. Rimer, D. W. Barrett, M. A. Maldonado, V. M. Vock, and F. Gonzalez-Lima, "Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition," *NeuroReport*, vol. 16, no. 3, pp. 271–275, 2005.
- [90] Y.-J. J. Chen, M. A. Johnson, M. D. Lieberman et al., "Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components," *The Journal of Neuroscience*, vol. 28, no. 27, pp. 6872–6883, 2008.
- [91] J.-C. Pei, C.-M. Liu, and W.-S. Lai, "Distinct phenotypes of new transmembrane-domain neuregulin 1 mutant mice and the rescue effects of valproate on the observed schizophrenia-related cognitive deficits," *Frontiers in Behavioral Neuroscience*, vol. 8, article 126, 2014.
- [92] C. O'Leary, L. Desbonnet, N. Clarke et al., "Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1," *Neuroscience*, vol. 277, pp. 294–305, 2014.
- [93] D. H. R. Blackwood, A. Fordyce, M. T. Walker, D. M. St. Clair, D. J. Porteous, and W. J. Muir, "Schizophrenia and affective disorders— cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family," *American Journal of Human Genetics*, vol. 69, no. 2, pp. 428–433, 2001.
- [94] N. A. Sachs, A. Sawa, S. E. Holmes, C. A. Ross, L. E. DeLisi, and R. L. Margolis, "A frameshift mutation in disrupted in schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder," *Molecular Psychiatry*, vol. 10, no. 8, pp. 758–764, 2005.
- [95] N. J. Bradshaw and D. J. Porteous, "DISC1-binding proteins in neural development, signalling and schizophrenia," *Neuropharmacology*, vol. 62, no. 3, pp. 1230–1241, 2012.
- [96] N. J. Brandon and A. Sawa, "Linking neurodevelopmental and synaptic theories of mental illness through DISC1," *Nature Reviews Neuroscience*, vol. 12, no. 12, pp. 707–722, 2011.
- [97] S. J. Clapcote, T. V. Lipina, J. K. Millar et al., "Behavioral phenotypes of Disc1 missense mutations in mice," *Neuron*, vol. 54, no. 3, pp. 387–402, 2007.
- [98] T. Hikida, H. Jaaro-Peled, S. Seshadri et al., "Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 36, pp. 14501–14506, 2007.
- [99] W. Li, Y. Zhou, J. D. Jentsch et al., "Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 46, pp. 18280–18285, 2007.
- [100] M. Kvajo, H. McKellar, P. A. Arguello et al., "A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 19, pp. 7076–7081, 2008.
- [101] M. V. Pletnikov, Y. Ayhan, O. Nikolskaia et al., "Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia," *Molecular Psychiatry*, vol. 13, no. 2, pp. 173–186, 2008.
- [102] S. Shen, B. Lang, C. Nakamoto et al., "Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated DISC1," *The Journal of Neuroscience*, vol. 28, no. 43, pp. 10893–10904, 2008.
- [103] Y. Mao, X. Ge, C. L. Frank et al., "Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3 β / β -catenin signaling," *Cell*, vol. 136, no. 6, pp. 1017–1031, 2009.
- [104] T. V. Lipina, C. Zai, D. Hlousek, J. C. Roder, and A. H. C. Wong, "Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviors in mice," *The Journal of Neuroscience*, vol. 33, no. 18, pp. 7654–7666, 2013.
- [105] D. Ibi, T. Nagai, Y. Kitahara et al., "Neonatal polyI:C treatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood," *Neuroscience Research*, vol. 64, no. 3, pp. 297–305, 2009.
- [106] T. Nagai, Y. Kitahara, D. Ibi, T. Nabeshima, A. Sawa, and K. Yamada, "Effects of antipsychotics on the behavioral deficits in human dominant-negative DISC1 transgenic mice with neonatal polyI:C treatment," *Behavioural Brain Research*, vol. 225, no. 1, pp. 305–310, 2011.
- [107] B. Abazyan, J. Dziedzic, K. Hua et al., "Chronic exposure of mutant DISC1 mice to lead produces sex-dependent abnormalities consistent with schizophrenia and related mental disorders: a gene-environment interaction study," *Schizophrenia Bulletin*, vol. 40, no. 3, pp. 575–584, 2014.
- [108] B. Kadkhodaei, T. Ito, E. Joodmardi et al., "Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons," *The Journal of Neuroscience*, vol. 29, no. 50, pp. 15923–15932, 2009.
- [109] P. Rojas, E. Joodmardi, Y. Hong, T. Perlmann, and S. O. Ögren, "Adult mice with reduced Nurr1 expression: an animal model

- for schizophrenia," *Molecular Psychiatry*, vol. 12, no. 8, pp. 756–766, 2007.
- [110] S. Vuillermot, E. Joodmardi, T. Perlmann, S. O. Ögren, J. Feldon, and U. Meyer, "Prenatal immune activation interacts with genetic *Nurr1* deficiency in the development of attentional impairments," *The Journal of Neuroscience*, vol. 32, no. 2, pp. 436–451, 2012.
- [111] B. Hibell, U. Guttormsson, S. Ahlström et al., *The 2011 ESPAD Report. Substance Use Among Students in 36 European Countries*, The Swedish Council for Information on Alcohol and Other Drugs (CAN), Stockholm, Sweden, 2012.
- [112] L. D. Johnston, P. M. O'Malley, J. G. Bachman et al., *Monitoring the Future National Survey Results on Drug Use, 1975–2013: Volume I, Secondary School Students*, Institute for Social Research, The University of Michigan, Ann Arbor, Mich, USA, 2014.
- [113] D. Linszen and T. van Amelsvoort, "Cannabis and psychosis: an update on course and biological plausible mechanisms," *Current Opinion in Psychiatry*, vol. 20, no. 2, pp. 116–120, 2007.
- [114] T. H. Moore, S. Zammit, A. Lingford-Hughes et al., "Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review," *The Lancet*, vol. 370, no. 9584, pp. 319–328, 2007.
- [115] D. M. Fergusson, L. J. Horwood, and N. R. Swain-Campbell, "Cannabis dependence and psychotic symptoms in young people," *Psychological Medicine*, vol. 33, no. 1, pp. 15–21, 2003.
- [116] L. Arseneault, M. Cannon, R. Poulton, R. Murray, A. Caspi, and T. E. Moffitt, "Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study," *British Medical Journal*, vol. 325, no. 7374, pp. 1212–1213, 2002.
- [117] L. Arseneault, M. Cannon, J. Witton, and R. M. Murray, "Causal association between cannabis and psychosis: examination of the evidence," *British Journal of Psychiatry*, vol. 184, pp. 110–117, 2004.
- [118] J. McGrath, J. Welham, J. Scott et al., "Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults," *Archives of General Psychiatry*, vol. 67, no. 5, pp. 440–447, 2010.
- [119] J. Decoster, J. van Os, I. Myin-Germeys, M. De Hert, and R. van Winkel, "Genetic variation underlying psychosis-inducing effects of cannabis: critical review and future directions," *Current Pharmaceutical Design*, vol. 18, no. 32, pp. 5015–5023, 2012.
- [120] R. Van Winkel, G. Esquivel, G. Kenis et al., "Genome-wide findings in schizophrenia and the role of gene-environment interplay," *CNS Neuroscience and Therapeutics*, vol. 16, no. 5, pp. e185–e192, 2010.
- [121] L. French, C. Gray, G. Leonard et al., "Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence," *JAMA Psychiatry*, vol. 72, no. 10, pp. 1002–1011, 2015.
- [122] D. Goldman, "America's cannabis experiment," *JAMA Psychiatry*, vol. 72, no. 10, pp. 969–970, 2015.
- [123] C. M. P. O'Tuathaigh, M. Hryniewiecka, A. Behan et al., "Chronic adolescent exposure to δ -9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes," *Neuropsychopharmacology*, vol. 35, no. 11, pp. 2262–2273, 2010.
- [124] M. Schneider and M. Koch, "Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats," *Neuropsychopharmacology*, vol. 28, no. 10, pp. 1760–1769, 2003.
- [125] J. Renard, L. G. Rosen, M. Loureiro et al., "Adolescent cannabinoid exposure induces a persistent sub-cortical hyper-dopaminergic state and associated molecular adaptations in the prefrontal cortex," *Cerebral Cortex*, 2016.
- [126] P. D. Morrison and R. M. Murray, "From real-world events to psychosis: the emerging neuropharmacology of delusions," *Schizophrenia Bulletin*, vol. 35, no. 4, pp. 668–674, 2009.
- [127] S. Han, B.-Z. Yang, H. R. Kranzler et al., "Linkage analysis followed by association show *NRG1* associated with cannabis dependence in African Americans," *Biological Psychiatry*, vol. 72, no. 8, pp. 637–644, 2012.
- [128] A. A. Boucher, G. E. Hunt, T. Karl, J. Micheau, I. S. McGregor, and J. C. Arnold, "Heterozygous neuregulin 1 mice display greater baseline and Δ^9 -tetrahydrocannabinol-induced c-Fos expression," *Neuroscience*, vol. 149, no. 4, pp. 861–870, 2007.
- [129] A. A. Boucher, J. C. Arnold, L. Duffy, P. R. Schofield, J. Micheau, and T. Karl, "Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Δ^9 -tetrahydrocannabinol," *Psychopharmacology*, vol. 192, no. 3, pp. 325–336, 2007.
- [130] L. E. Long, R. Chesworth, J. C. Arnold, and T. Karl, "A follow-up study: acute behavioural effects of Δ^9 -THC in female heterozygous neuregulin 1 transmembrane domain mutant mice," *Psychopharmacology*, vol. 211, no. 3, pp. 277–289, 2010.
- [131] A. A. Boucher, G. E. Hunt, J. Micheau et al., "The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids," *International Journal of Neuropsychopharmacology*, vol. 14, no. 5, pp. 631–643, 2011.
- [132] L. E. Long, R. Chesworth, X.-F. Huang, I. S. McGregor, J. C. Arnold, and T. Karl, "Transmembrane domain *Nrg1* mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence," *International Journal of Neuropsychopharmacology*, vol. 16, no. 1, pp. 163–175, 2013.
- [133] J. R. Spencer, K. M. E. Darbyshire, A. A. Boucher et al., "Novel molecular changes induced by *Nrg1* hypomorphism and *Nrg1*-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice," *Frontiers in Cellular Neuroscience*, vol. 7, article 15, 2013.
- [134] J. A. S. Crippa, G. N. Derenusson, T. B. Ferrari et al., "Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report," *Journal of Psychopharmacology*, vol. 25, no. 1, pp. 121–130, 2011.
- [135] F. M. Leweke, J. K. Mueller, B. Lange et al., "Therapeutic potential of cannabinoids in psychosis," *Biological Psychiatry*, vol. 79, no. 7, pp. 604–612, 2015.
- [136] L. E. Long, R. Chesworth, X.-F. Huang et al., "Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice," *PLoS ONE*, vol. 7, no. 4, Article ID e34129, 2012.
- [137] M. D. Ballinger, A. Saito, B. Abazyan et al., "Adolescent cannabis exposure interacts with mutant *DISC1* to produce impaired adult emotional memory," *Neurobiology of Disease*, vol. 82, pp. 176–184, 2015.
- [138] E. M. Tunbridge, D. R. Weinberger, and P. J. Harrison, "A novel protein isoform of catechol O-methyltransferase (COMT): brain expression analysis in schizophrenia and bipolar disorder and effect of Val¹⁵⁸Met genotype," *Molecular Psychiatry*, vol. 11, no. 2, pp. 116–117, 2006.
- [139] D. Collip, R. Van Winkel, O. Peerbooms et al., "COMT Val158Met-stress interaction in psychosis: role of background psychosis risk," *CNS Neuroscience and Therapeutics*, vol. 17, no. 6, pp. 612–619, 2011.

- [140] X. Goldberg, M. Fatjó-Vilas, S. Alemany, I. Nenadic, C. Gastó, and L. Fañanás, "Gene-environment interaction on cognition: a twin study of childhood maltreatment and COMT variability," *Journal of Psychiatric Research*, vol. 47, no. 7, pp. 989–994, 2013.
- [141] S. Alemany, B. Arias, M. Fatjó-Vilas et al., "Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes," *Acta Psychiatrica Scandinavica*, vol. 129, no. 1, pp. 54–62, 2014.
- [142] A. Caspi, T. E. Moffitt, M. Cannon et al., "Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction," *Biological Psychiatry*, vol. 57, no. 10, pp. 1117–1127, 2005.
- [143] C. M. P. O'Tuathaigh, G. Clarke, J. Walsh et al., "Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes," *International Journal of Neuropsychopharmacology*, vol. 15, no. 9, pp. 1331–1342, 2012.
- [144] Á. T. Behan, M. Hryniewiecka, C. M. P. O'Tuathaigh et al., "Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways," *Neuropsychopharmacology*, vol. 37, no. 7, pp. 1773–1783, 2012.
- [145] L. J. Phillips, P. D. McGorry, B. Garner et al., "Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders," *Australian and New Zealand Journal of Psychiatry*, vol. 40, no. 9, pp. 725–741, 2006.
- [146] K. D. Tessner, V. Mittal, and E. F. Walker, "Longitudinal study of stressful life events and daily stressors among adolescents at high risk for psychotic disorders," *Schizophrenia Bulletin*, vol. 37, no. 2, pp. 432–441, 2011.
- [147] F. Varese, E. Barkus, and R. P. Bentall, "Dissociation mediates the relationship between childhood trauma and hallucination-proneness," *Psychological Medicine*, vol. 42, no. 5, pp. 1025–1036, 2012.
- [148] J.-P. Selten and E. Cantor-Graae, "Hypothesis: social defeat is a risk factor for schizophrenia?" *The British Journal of Psychiatry*, vol. 191, no. 51, pp. s9–s12, 2007.
- [149] J.-P. Selten, E. van der Ven, B. P. F. Rutten, and E. Cantor-Graae, "The social defeat hypothesis of schizophrenia: an update," *Schizophrenia Bulletin*, vol. 39, no. 6, pp. 1180–1186, 2013.
- [150] C. Hammels, E. Pishva, J. De Vry et al., "Defeat stress in rodents: from behavior to molecules," *Neuroscience and Biobehavioral Reviews*, vol. 59, pp. 111–140, 2015.
- [151] O. Berton, C. A. McClung, R. J. DiLeone et al., "Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress," *Science*, vol. 311, no. 5762, pp. 864–868, 2006.
- [152] V. Krishnan, M. Han, D. L. Graham et al., "Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions," *Cell*, vol. 131, no. 2, pp. 391–404, 2007.
- [153] T. W. Chohan, A. A. Boucher, J. R. Spencer et al., "Partial genetic deletion of neuregulin 1 modulates the effects of stress on sensorimotor gating, dendritic morphology, and HPA axis activity in adolescent mice," *Schizophrenia Bulletin*, vol. 40, no. 6, pp. 1272–1284, 2014.
- [154] F. N. Haque, T. V. Lipina, J. C. Roder, and A. H. C. Wong, "Social defeat interacts with Discl mutations in the mouse to affect behavior," *Behavioural Brain Research*, vol. 233, no. 2, pp. 337–344, 2012.
- [155] M. Niwa, H. Jaaro-Peled, S. Tankou et al., "Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids," *Science*, vol. 339, no. 6117, pp. 335–339, 2013.
- [156] R. E. Straub, Y. Jiang, C. J. MacLean et al., "Genetic variation in the 6p22.3 Gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia," *American Journal of Human Genetics*, vol. 71, no. 2, pp. 337–348, 2002.
- [157] B. Riley, P.-H. Kuo, B. S. Maher et al., "The dystrobrevin binding protein 1 (DTNBP1) gene is associated with schizophrenia in the Irish Case Control Study of Schizophrenia (ICSS) sample," *Schizophrenia Research*, vol. 115, no. 2-3, pp. 245–253, 2009.
- [158] M. Ayalew, H. Le-Niculescu, D. F. Levey et al., "Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction," *Molecular Psychiatry*, vol. 17, no. 9, pp. 887–905, 2012.
- [159] K. E. Burdick, T. E. Goldberg, B. Funke et al., "DTNBP1 genotype influences cognitive decline in schizophrenia," *Schizophrenia Research*, vol. 89, no. 1-3, pp. 169–172, 2007.
- [160] A. J. Fallgatter, A.-C. Ehlis, M. J. Herrmann et al., "DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in schizophrenic patients—support for the glutamate hypothesis of schizophrenias," *Genes, Brain and Behavior*, vol. 9, no. 5, pp. 489–497, 2010.
- [161] J.-P. Zhang, K. E. Burdick, T. Lencz, and A. K. Malhotra, "Meta-analysis of genetic variation in DTNBP1 and general cognitive ability," *Biological Psychiatry*, vol. 68, no. 12, pp. 1126–1133, 2010.
- [162] C. S. Weickert, D. A. Rothmond, T. M. Hyde, J. E. Kleinman, and R. E. Straub, "Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients," *Schizophrenia Research*, vol. 98, no. 1-3, pp. 105–110, 2008.
- [163] J. Tang, R. P. LeGros, N. Louneva et al., "Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression," *Human Molecular Genetics*, vol. 18, no. 20, pp. 3851–3863, 2009.
- [164] C. Fu, D. Chen, R. Chen, Q. Hu, G. Wang, and K.-L. Lim, "The schizophrenia-related protein dysbindin-1A is degraded and facilitates NF-Kappa B activity in the nucleus," *PLoS ONE*, vol. 10, no. 7, Article ID e0132639, 2015.
- [165] R. T. Swank, H. O. Sweet, M. T. Davisson, M. Reddington, and E. K. Novak, "Sandy: a new mouse model for platelet storage pool deficiency," *Genetical Research*, vol. 58, no. 1, pp. 51–62, 1991.
- [166] K. Takao, K. Toyama, K. Nakanishi et al., "Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia," *Molecular Brain*, vol. 1, article 11, 2008.
- [167] J. D. Jentsch, H. Trantham-Davidson, C. Jairl, M. Tinsley, T. D. Cannon, and A. Lavin, "Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice," *Neuropsychopharmacology*, vol. 34, no. 12, pp. 2601–2608, 2009.
- [168] K. H. Karlsgodt, K. Robleto, H. Trantham-Davidson et al., "Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance," *Biological Psychiatry*, vol. 69, no. 1, pp. 28–34, 2011.
- [169] F. Papaleo, F. Yang, S. Garcia et al., "Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways," *Molecular Psychiatry*, vol. 17, no. 1, pp. 85–98, 2012.
- [170] W. B. Glen Jr, B. Horowitz, G. C. Carlson et al., "Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and

- contextual fear conditioning," *Hippocampus*, vol. 24, no. 2, pp. 204–213, 2014.
- [171] S. K. Bhardwaj, R. T. Ryan, T. P. Wong, and L. K. Srivastava, "Loss of dysbindin-1, a risk gene for schizophrenia, leads to impaired group 1 metabotropic glutamate receptor function in mice," *Frontiers in Behavioral Neuroscience*, vol. 9, article 72, 2015.
- [172] F. Papaleo and D. R. Weinberger, "Dysbindin and Schizophrenia: it's dopamine and glutamate all over again," *Biological Psychiatry*, vol. 69, no. 1, pp. 2–4, 2011.
- [173] M. M. Cox, A. M. Tucker, J. Tang et al., "Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background," *Genes, Brain and Behavior*, vol. 8, no. 4, pp. 390–397, 2009.
- [174] K. K. Nicodemus, S. Marenco, A. J. Batten et al., "Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk," *Molecular Psychiatry*, vol. 13, no. 9, pp. 873–877, 2008.
- [175] J. Voisey, C. D. Swagell, I. P. Hughes et al., "A polymorphism in the dysbindin gene (DTNBP1) associated with multiple psychiatric disorders including schizophrenia," *Behavioral and Brain Functions*, vol. 6, article 41, 2010.
- [176] S. Hattori, T. Murotani, S. Matsuzaki et al., "Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia," *Biochemical and Biophysical Research Communications*, vol. 373, no. 2, pp. 298–302, 2008.
- [177] C. A. Ghiani, M. Starcevic, I. A. Rodriguez-Fernandez et al., "The dysbindin-containing complex (BLOC-1) in brain: developmental regulation, interaction with SNARE proteins and role in neurite outgrowth," *Molecular Psychiatry*, vol. 15, no. 2, pp. 204–215, 2010.
- [178] T. C. Südhof and J. E. Rothman, "Membrane fusion: grappling with SNARE and SM proteins," *Science*, vol. 323, no. 5913, pp. 474–477, 2009.
- [179] C. M. Lewis, D. F. Levinson, L. H. Wise et al., "Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia," *American Journal of Human Genetics*, vol. 73, no. 1, pp. 34–48, 2003.
- [180] J. Lochman, V. J. Balcar, F. Štátný, and O. Šerý, "Preliminary evidence for association between schizophrenia and polymorphisms in the regulatory regions of the ADRA2A, DRD3 and SNAP-25 genes," *Psychiatry Research*, vol. 205, no. 1–2, pp. 7–12, 2013.
- [181] X. Fan and E. J. Hess, "D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD," *Neurobiology of Disease*, vol. 26, no. 1, pp. 201–211, 2007.
- [182] X. Fan, M. Xu, and E. J. Hess, "D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD," *Neurobiology of Disease*, vol. 37, no. 1, pp. 228–236, 2010.
- [183] P. L. Oliver and K. E. Davies, "Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk," *Human Molecular Genetics*, vol. 18, no. 23, pp. 4576–4589, 2009.
- [184] M. Baca, A. M. Allan, L. D. Partridge, and M. C. Wilson, "Gene-environment interactions affect long-term depression (LTD) through changes in dopamine receptor affinity in Snap25 deficient mice," *Brain Research*, vol. 1532, pp. 85–98, 2013.
- [185] T. Niitsu, T. Ishima, T. Yoshida et al., "A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia," *Psychiatry Research*, vol. 215, no. 2, pp. 268–273, 2014.
- [186] C. Theleritis, H. L. Fisher, I. Schäfer et al., "Brain derived neurotrophic factor (BDNF) is associated with childhood abuse but not cognitive domains in first episode psychosis," *Schizophrenia Research*, vol. 159, no. 1, pp. 56–61, 2014.
- [187] E. Dong, P. Tueting, F. Matrisciano, D. R. Grayson, and A. Guidotti, "Behavioral and molecular neuroepigenetic alterations in prenatally stressed mice: relevance for the study of chromatin remodeling properties of antipsychotic drugs," *Translational Psychiatry*, vol. 6, article e711, 2016.
- [188] E. E. Manning, A. L. Halberstadt, and M. van den Buuse, "BDNF-deficient mice show reduced psychosis-related behaviors following chronic methamphetamine," *International Journal of Neuropsychopharmacology*, vol. 19, no. 4, 2016.
- [189] E. E. Manning and M. van den Buuse, "BDNF deficiency and young-adult methamphetamine induce sex-specific effects on prepulse inhibition regulation," *Frontiers in Cellular Neuroscience*, vol. 7, article 92, 2013.
- [190] S. H. Fatemi, J. A. Earle, and T. McMenemy, "Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression," *Molecular Psychiatry*, vol. 5, no. 6, pp. 654–663, 2000.
- [191] I. Knuesel, "Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases," *Progress in Neurobiology*, vol. 91, no. 4, pp. 257–274, 2010.
- [192] G. Laviola, E. Ognibene, E. Romano, W. Adriani, and F. Keller, "Gene-environment interaction during early development in the heterozygous reeler mouse: clues for modelling of major neurobehavioral syndromes," *Neuroscience and Biobehavioral Reviews*, vol. 33, no. 4, pp. 560–572, 2009.
- [193] E. Ognibene, W. Adriani, S. Macri, and G. Laviola, "Neurobehavioral disorders in the infant reeler mouse model: interaction of genetic vulnerability and consequences of maternal separation," *Behavioural Brain Research*, vol. 177, no. 1, pp. 142–149, 2007.
- [194] K. R. Howell and A. Pillai, "Effects of prenatal hypoxia on schizophrenia-related phenotypes in heterozygous reeler mice: a gene × environment interaction study," *European Neuropsychopharmacology*, vol. 24, no. 8, pp. 1324–1336, 2014.
- [195] Y. Ayhan, A. Sawa, C. A. Ross, and M. V. Pletnikov, "Animal models of gene-environment interactions in schizophrenia," *Behavioural Brain Research*, vol. 204, no. 2, pp. 274–281, 2009.
- [196] E. L. Burrows, C. E. McOmish, and A. J. Hannan, "Gene-environment interactions and construct validity in preclinical models of psychiatric disorders," *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 35, no. 6, pp. 1376–1382, 2011.
- [197] I. Myin-Germeys, P. Delespaul, and J. van Os, "Behavioural sensitization to daily life stress in psychosis," *Psychological Medicine*, vol. 35, no. 5, pp. 733–741, 2005.
- [198] R. D. Goodwin, X. F. Amador, D. Malaspina, S. A. Yale, R. R. Goetz, and J. M. Gorman, "Anxiety and substance use comorbidity among inpatients with schizophrenia," *Schizophrenia Research*, vol. 61, no. 1, pp. 89–95, 2003.
- [199] I. Myin-Germeys, M. Oorschot, D. Collip, J. Lataster, p. delespaul, and J. van Os, "Experience sampling research in psychopathology: opening the black box of daily life," *Psychological Medicine*, vol. 39, no. 9, pp. 1533–1547, 2009.
- [200] J. M. Goldstein, L. J. Seidman, J. M. Goodman et al., "Are there sex differences in neuropsychological functions among patients

- with schizophrenia?" *American Journal of Psychiatry*, vol. 155, no. 10, pp. 1358–1364, 1998.
- [201] M. Han, X.-F. Huang, D. C. Chen et al., "Gender differences in cognitive function of patients with chronic schizophrenia," *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 39, no. 2, pp. 358–363, 2012.
- [202] D. A. Lewis, A. A. Curley, J. R. Glausier, and D. W. Volk, "Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia," *Trends in Neurosciences*, vol. 35, no. 1, pp. 57–67, 2012.
- [203] S. Canetta, S. Bolkan, N. Padilla-Coreano et al., "Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons," *Molecular Psychiatry*, vol. 21, no. 7, pp. 956–968, 2016.
- [204] J. van Os and S. Kapur, "Schizophrenia," *The Lancet*, vol. 374, no. 9690, pp. 635–645, 2009.
- [205] R. M. Murray, L. Sideli, C. La Cascia, and D. La Barbera, "Bridging the gap between research into biological and psychosocial models of psychosis," *Shanghai Archives of Psychiatry*, vol. 27, no. 3, pp. 139–143, 2015.
- [206] O. D. Howes, C. McDonald, M. Cannon, L. Arseneault, J. Boydell, and R. M. Murray, "Pathways to schizophrenia: the impact of environmental factors," *International Journal of Neuropsychopharmacology*, vol. 7, no. 1, pp. S7–S13, 2004.
- [207] P. J. Harrison and D. R. Weinberger, "Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence," *Molecular Psychiatry*, vol. 10, no. 1, pp. 40–68, 2005.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

